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A Novel Biostable 3D Porous Collagen Scaffold for Implantable Biosensor
Young Min Ju
ABSTRACT
Diabetes is a chronic metabolic disorder whereby the body loses its
ability to maintain normal glucose levels. Despite of development of implantable
glucose sensors in long periods, none of the biosensors are capable of
continuously monitoring glucose levels during long-term implantation reliably.
Progressive loss of sensor function occurs due in part to biofouling and to the
consequences of a foreign body response such as inflammation, fibrosis, and
loss of vasculature.
In order to improve the function and lifetime of implantable glucose
sensors, a new 3D porous and bio-stable collagen scaffold has been developed
to improve the biocompatibility of implantable glucose sensors. The novel
collagen scaffold was crosslinked using nordihydroguaiaretic acid (NDGA) to
enhance biostability. NDGA-treated collagen scaffolds were stable without any
physical deformation in the subcutaneous tissue of rats for 4 weeks. The scaffold
application does not impair the function of our sensor. The effect of the scaffolds
on sensor function and biocompatibility was examined during long-term in vitro
and in vivo experiments and compared with control bare sensors. The sensitivity
of the short sensors was greater than the sensitivity of long sensors presumably
x

due to less micro-motions in the sub-cutis of the rats. The NDGA-crosslinked
scaffolds induced much less inflammation and retained their physical structure in
contrast to the glutaraldehyde (GA)-crosslinked scaffolds.
We also have developed a new dexamethasone (Dex, anti-inflammatory
drug)-loaded poly(lactic-co-glycolic acid) (PLGA) microspheres/porous collagen
scaffold composite for implantable glucose sensors. The composite system
showed a much slower and sustained drug release than the standard
microspheres. The composite system was also shown to not significantly affect
the function of the sensors. The sensitivity of the sensors with the composite
system in vivo remained higher than for sensors without the composites (no
scaffold, scaffold without microspheres). Histology showed that the inflammatory
response to the Dex-loaded composite was much lower than for the control
scaffold. The Dex-loaded composite system might be useful to reduce
inflammation to glucose sensors and therefore extend their function and lifetime.

xi

CHAPTER 1
INTRODUCTION

1.1. Diabetes
Diabetes is a chronic metabolic disorder in which the body loses its ability
to maintain normal glucose levels. Diabetes is the 6th leading cause of death by
disease and is rapidly increasing in the United States and around the world. The
American Diabetes Association (ADA) estimates that at least 20.8 million or 7%
of Americans have suffered from diabetes, caused by a lack or shortage of
insulin, the hormone that allows glucose to enter the body’s cells and be stored
or used for physiological activation energy [1,2].
There are two major types of diabetes (Type I and II). Type I, or insulindependent diabetes, is an autoimmune disease. It is marked by blood sugar
levels rising out of control because the body’s immune system destroys the
insulin-producing beta cells in the pancreas. The pancreas then produces little or
no insulin. Approximately, 5-10% of diabetes cases in the US is Type I. Type II
diabetes is the most common form of diabetes. It is characterized clinically by
hyperglycemia and insulin resistance, which results when the insulin produced,
does not adequately control the uptake of glucose by the cells. Type II diabetes
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is usually the type of diabetes diagnosed in patients that are over 30 years old or
obese. Ninety percent of diabetes cases is Type II [2-4].
Diabetes has acute and chronic effects on the body, and may lead to
death. Persistent abnormal high levels of blood glucose can slowly damage both
the small and large blood vessels in the body, resulting in numerous
complications [2,3], such as:
-

Heart disease and stroke

-

High blood pressure

-

Blindness

-

Kidney disease

-

Nervous system disease

-

Amputations

-

Dental disease

-

Complications of pregnancy

-

Erectile dysfunction

Thus, physicians and researchers are trying to develop better ways of monitoring
and curing diabetes to avoid life-threatening events.

2

1.2. Implantable Glucose Sensor
The ADA’s Consensus Statement on Self-Monitoring of Blood Glucose
(SMBG) recommends that diabetic patients should test their blood glucose level
at least twice for Type II diabetes and four (for Type I diabetes) times a day [5].
To maintain normal or near normal blood glucose levels (70-120 mg/dL), diabetic
patients require injections of insulin, and have to monitor their own blood glucose
levels throughout the day. However, the general use of over-the-counter glucose
meters requires finger pricking to obtain blood samples several times each day.
Because of the high density sensory neurons located in the dermis on the finger
tip, patients frequent suffer from painful [6]. Thus, the painfulness, inconvenience,
and discomfort of self-monitoring of blood glucose are frequent obstacle to
effective patient compliance and optimal management of diabetes.
To corrective regulate tight blood glucose control, a continuous glucose
monitoring system (CGMS) is required. The CGMS can provide additional data to
track unpredictable glucose trend in relation to meals and exercise [Fig. 1.1] and
allow hypoglycemic and hyperglycemic excursions to be avoided. During the past
thirty years many kinds of continuous glucose monitoring systems have been
studied. These include sensors implanted in the subcutaneous tissue [7-13],
sensors implanted in the vascular bed [14,15], and determining glucose
concentration in interstitial fluid sampled using a micro dialysis device [16-18].
Although several studies of implantable glucose sensors have been reported,
none of the biosensors tested well capable of reliable in continuous blood
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Figure 1.1.

Demonstration of Glucose Rise and Fall in Relation to Meals
and Exercise. Figure adapted from Joseph and Torjman [19].

4

glucose monitoring during long-term implantation, progressive loss of sensor
function occurred due in part to biofouling and to the consequences of a foreign
body response, such as inflammation, fibrosis, and loss of vasculature [20-22].
Most of the implantable glucose sensors are based on amperometric
enzyme sensors from the pioneering work of Clark and Lyons [23], Updike and
Hicks [24], and Gough et al. [25]. The typical enzyme-based amperometric
sensor is composed of a two-electrode system with a glucose indicating platinum
(Pt) working electrode and a silver/silver chloride (Ag/AgCl) reference-counter
electrode. Figure 1.2 shows the needle-type implantable glucose sensor
commonly used for subcutaneous insertion [26]. An outer layer of polyurethane
membrane is permeable to glucose and oxygen but impermeable to most
interfering substances. A crosslinked glucose oxidase (GOD) enzyme layer is
sandwiched between inner and outer membrane. In the presence of oxygen,
glucose is oxidized by GOD and produces hydrogen peroxide (H2O2). Hydrogen
peroxide is then oxidized electrochemically at the Pt electrode surface using a
polarization voltage of about +700 mV, producing 2e- that is detected as a current
[21,27]. The chemical reactions are:

⎯→ Gluconic Acid + H2O2
Glocose + O2 ⎯⎯
GOD

+700 mV

⎯→ 2e- + 2H+ + O2
H2O2 ⎯⎯ ⎯

5

Figure 1.2. Schematic Illustration of the Needle-type Implantable Glucose Sensor.
Figure adapted from Pickup et al. [26].
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1.3. Biocompatibility of Implanted Devices
Most implanted medical devices, including biosensors, frequently
encounter a sequence of common host defense mechanisms, such as acute and
chronic inflammation, wound healing, and foreign body responses [28] [Fig. 1.3].
Acute inflammation begins within a few minutes after device implantation, with
accumulation of interstitial fluid, plasma proteins, and migration of leukocytes
(neutrophils, monocytes, macrophages) around sensors. Chronic inflammation
follows if acute inflammation is not resolved. In general, macrophages rapidly
differentiate from monocytes and become the predominant cell type in exudates
surrounding the devices. The macrophages are key mediators in the
development of immune reactions to implanted synthetic biomaterials. They also
produce and secrete a number of biologically active products including
chemotactic factors, reactive oxygen metabolites, growth factors, and cytokines
[29]. Wound healing is the repair and remodeling process which occurs after. It
takes place in the space between the implant and the surrounding tissue. It is
begun by the action of monocytes and macrophages, followed by proliferation of
fibroblasts and vascular endothelial cells at the wound site. The fibroblasts and
new small blood vessels proliferate in developing granulation tissue [28]. The
new small blood vessels are budded or sprouted from preexisting blood vessels.
This process is called neovascularization or angiogenesis [30-32]. Fibroblasts
also synthesize type III collagen and proteoglycans at the wound site. Eventually,
collagen deposition may result in the formation of fibrous capsule around the
implanted device.
7

Figure 1.3.

Temporal Variation in Tissue Reaction to Implanted Biomaterials.
Figure adapted from Anderson [28].
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The foreign body reaction has a connection with foreign body giant cells
and granulation tissue including macrophages, fibroblasts and new capillaries at
the tissue-implant interface. Fibrosis or fibrous encapsulation is the end-stage of
the healing process. Fibrotic tissue surrounding the implanted device isolates it
from the local tissue environment. Figure 1.4 shows the process of wound
healing in the presence of an implant.
Pore size and pore density on the surface of implanted device (i.e.
scaffold) may greatly influence fibrous capsule thickness, blood vessel density,
and the location of vessels within the three-dimensional scaffold [19]. Large pore
scaffolds (pores > 8 microns in diameter) allow deep penetration of capillaries
and supporting extra-cellular matrix (ECM). Sharkawy et al. [33] showed that
after four weeks of subcutaneous implantation in rat, well-organized collagen
capsule typical of foreign-body responses around non-porous implants, while
porous implants produced less fibrosis and more vascularized fibrous capsules.
For implantable biosensors, adsorption of proteins and cells as well as the
formation of a fibrous capsule tissue can severely hinder transport of small
molecules, i.e. glucose. Glucose is not able to freely diffuse from capillary blood
to the sensor’s transducer surface [21]. Pickup et al. [26] reported an example of
protein and cellular accumulation on the tips of the non-functioned glucose
sensors after only five hours of implantation [Fig. 1.5]. Ertefai and Gough [13]
showed fibrous capsule tissue surrounding a glucose sensor tip after 10 days of
implantation in subcutis [Fig. 1.6].

9

Reichert and Sharkawy [21] reviewed the findings of several implantable
biosensor studies:
- Inflammatory cells bind to and degrade sensor performance.
- Protein adsorption hinders sensor function by lowering permeability to
glucose and oxygen.
- Fibrous tissue and exogenous pool of foreign body capsule (FBC)
presents a transport barrier to glucose.
- Vascularization of the FBC is necessary for good long-term stability of
response.
- Sensors inactivated in vivo often regain function when FBC is removed
and retested in vitro.
- Sensor baseline and sensitivity gradually degrade with implantation time.
- Sensor performance is erratic for the first hour and then becomes steady
upon equilibration.
- Subcutaneous (SQ) glucose levels lag behind plasma levels by 5-20 min.
- Intravascular (IV) implantation gives immediate glucose readings but
suffers from thrombus formation.
- IV implantation is best if the sensor is placed in fast-moving blood
stream.
- Intraperitoneal (IP) FBC is thinner than SQ.
- Textured coatings produce vascularized FBC that might ensure longterm SQ sensor accuracy.

10

Figure 1.4.

Schematic of Process of Wound Healing in the Presence of an
Implant. Figure adapted from Cannas et al. [34].
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A

B

Figure 1.5.

C

SEM Photographs of Tips of Glucose Sensors. (A) Control
sensornot implanted; (B) Functioning sensor showing minimal
biofouling; (C) Non-functioning sensor showing significant protein
and Cellular accumulation. Figure adapted from Pickup et al. [26].
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Figure 1.6.

Light Micrograph Image of Glucose Sensor Tip after 10 Days of
Implantation in Subcutis. Note dense fibrous capsule surrounds
sensor. Figure adapted from Pickup et al. [13].
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1.4. Strategies for Biocompatible Implantable Sensors
Many researchers studied sensor modification to reduce sensor
membrane biofouling in vivo. One approach is to reduce protein adsorption.
Quinn et al. [35] used poly(ethylene glycol) (PEG) into a poly(hydroxyethylmethacrylate) (PHEMA) for surface modification of the biosensor. The PEG
chains tend to stand perpendicular to the membrane surface to provide a water
rich phase that resists many protein molecules. Vadgama et al. [36,37] tried to
reduce protein adsorption by using diamond-like carbon, so-called “inert”
materials. Shichiri et al. [38] incorporated an alginate/polylysine gel layer on the
sensor. Shaw et al. [39] reported biocompatibility improvement of biosensor,
coated with PHEMA/polyurethane (PU). Wilkins et al. [40] and Moussy et al.
[7,41-43] introduced the NafionTM (perfluorosulphonic acid) membrane, to reduce
biofouling on surface of the sensor and reduce interference from urate and
ascorbate. Armour et al. [14] coated their sensor tips with crosslinked albumin
and Kerner et al. [44] developed cellulose-coated sensors to improve sensor
blood compatibility.
Controlled delivery of tissue response modifiers (TRM) can be used to
control tissue responses. Dexamethasone (Dex), a synthetic glucocorticoid, is
well known for its immunosuppressive and anti-inflammatory function [45-47].
The biosensor design could incorporate this anti-inflammatory agent, which could
be slowly released using biodegradable microspheres [48,49]. Typically,
microspheres are prepared using natural or synthetic biodegradable polymers
such as poly(lactic-co-glycolic acid) (PLGA) [49]. Moussy et al. [50,51] developed
14

Dex/PLGA microspheres designed to suppress the inflammatory tissue response
to an implanted biosensor. Norton et al. [52] and Patil et al. [53] modified
hydrogel coatings [PHEMA and poly(vinyl alcohol) (PVA) hydrogel, respectively]
to include Dex-loaded PLGA microspheres to improve implantable biosensor
biocompatibility.
The best tissue environment for an implantable biosensor is vascularized
tissue around sensor. Angiogenesis, which include as complex cascade of
events

involving

endothelial

cell

activation,

migration

and

proliferation,

organization into immature vessels, association of mural cells with the immature
vessels, and matrix deposition as the vessels mature [54,55], has been
extensively studied. The control of neovascularization has recently focused on
the use of angiogenic growth factors such as vascular endothelial growth factor
(VEGF) and platelet-derived growth factor (PDGF). VEGF is a specific mitogen
for initiating angiogenesis, specifically, for promoting vascular permeability,
prolifieration, and migration of endothelial cells [56]. PDGF promotes the
maturation of blood vessels by the recruitment of smooth muscle cells to the
endothelium lining of nascent vasculature [55,57].
The controlled release of VEGF and PDGF has been studied widely as a
strategy for increasing the blood vessel density surrounding implants [58-61].
Klueh et al. [62,63] developed an in vivo gene transfer system with VEGF and
found that the VEGF-biosensor systems induced neovascularization surrounding
the sensor and thereby enhanced biosensor function in vivo. Ward et al. [64]
reported that VEGF infused continuously for 28 days into rat subcutaneous tissue
15

from a model biosensor led to local vascularization of the surrounding foreign
body capsule. Norton et al. [52] modified their hydrogel biosensor coatings to
incorporate PLGA microspheres in order to release vascular endothelial growth
factor.
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1.5. Collagen and Its Use in Biomaterials
In recent years, collagen and its derived matrices have become the most
widely used natural polymers in the biomedical field including tissue engineering
due to their low antigenicity, biodegradability and good mechanical, hemostatic
and cell-binding properties [65-69]. A broad range of potentially manufactured
products based on collagen is covering many medical disciplines [70] (Table 1).
Collagen is a major protein of connective tissues in animals as well as a
key structural component of the extracelluar matrix. It is distributed in skin, bones,
teeth, tendons, eyes and most other tissues and organs [71,72]. The collagen
molecule is a rod-like structure with a molecular weight of about 300,000 which
forms a unique triple-helix configuration of three polypeptide subunits. Each
collagen molecule is organized in a regular and hierarchical pattern forming fibrils
and fibril bundles that result in a tough tissue [73,74]. The collagen family has
been reported to contain at least 19 distinct types. Among them, type I collagen
is the most abundant in higher order animals in the skin, tendon, bone, and most
collagenous tissue, while type II is found in cartilage, and type III is found,
together with type I, in skin, and blood vessels. Thus, type I collagen is
predominantly encountered in biomaterials application as bioprosthetic devices
and scaffolds [71,73].
In order to devise strategies for using collagen in the development of
advanced biomaterials for biomedical engineering, it is necessary to confer
mechanical strength and enzymatic degradation (e.g. collagenase) resistance by
introduction of chemical or physical crosslinking into the molecular structure.
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Table 1.1. Examples of Applications of Collagen-Based Medical Devices [71].
Medical Area

Application

Cardiovascular surgery Vessel replacement, heart valves
Dentistry

Periodontal attachment, alveolar ridge augmentation

Dermatology

Tissue augmentation

General surgery

Hernia repair, adhesion barriers, tissue adhesives

Neurosurgery

Nerve conduits, nerve repair

Ophthalmology

Corneal graft, vitreous replacement

Orthopedics

Bone repair, cartilage and ligament reconstruction

Otology

Tympanic membrane replacement

Urology

Ureter replacement, renal repair, urinary incontinence

Wound management

Dressings
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There are several methods for crosslinking collagen-based biomaterials.
Glutaraldehyde (GA) is the most widely used as a crosslinking agent for
collagen-based biomaterials [65,75]. At neutral pH, GA reacts with amino groups
and with other functional group in protein, including carboxy and amide group
[76]. However, GA induces cytotoxicity in vivo, caused by the presence of
unreacted residual groups or the release of monomers of small polymers during
enzymatic degradation [77,78]. To avoid cytotoxicity and calcification of GAcrosslinked collagen, polyepoxy compounds, including glycol and glycerol
polyglycidyl ethers, have been examined as potential collagen crosslinking
agents [79,80]. Polyepoxy compounds react with the free amines of lysine side
chains on neighboring proteins. The hexamethylene diisocyanate (HMDI),
homobifunctional reagent, has the ability to crosslink collagen via its lysine side
chains. Chvapil et al. [81,82] reported that HMDI is an effective method for
crosslinking of collagen and does not leave residues after crosslinking process.
Crosslinking with carbodiimide, 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide
(EDC) and N-hydroxysuccinimide (NHS) being the most widely used as
crosslinking agents, has the main advantage in that it only facilitates the
formation of amide bonds between amino group on the collagen molecules
without becoming part of the actual linkage [73]. This method provides good
biocompatibility and higher cellular differentiation potential [66,83,84]. Koob et al.
[85-88] has newly developed a process for polymerizing type I collagen fibers
with nordihydroguaiaretic acid (NDGA), a plant-derived compound. NDGA
crosslinking is effective at significantly improving the mechanical properties of
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synthetic collagen fibers. Also, NDGA- crosslinked collagen fibers did not elicit a
foreign body response nor did they stimulate an immune reaction in vivo during a
six week implantation period. In addition, various physical treatments including
ultra-violet or gamma-ray irradiation, and dehydrothermal treatment, have been
effectively used for introducing crosslinks to collagen matrices [89-92].
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CHAPTER 2
IN VITRO / IN VIVO STABILITY OF THE SCAFFOLDS AND IN VITRO
SENSITIVITY OF IMPLANTABLE GLUCOSE SENSORS WITH SCAFFOLDS

2.1. Introduction
To maintain near normal blood glucose levels (70-120 mg/dL), diabetic
patients widely use over-the-counter glucose meters, which require finger
pricking to obtain blood samples several times a day. The pain [6], inconvenience,
and discomfort of self-monitoring of blood glucose (SMBG) are frequently
obstacles to effective patient compliance and optimal management of diabetes.
During the past 20 years many kinds of continuous glucose monitoring systems
have been studied including sensors implanted in the subcutaneous tissue [7-13],
sensors implanted in the vascular bed [14,15], and determining glucose
concentration in interstitial fluid sampled using a micro dialysis device [16-18].
Although several studies of implantable glucose sensors have been reported,
none of these biosensors are capable of continuously monitoring glucose levels
during long-term implantation reliably. Progressive loss of sensor function occurs
due in part to biofouling and to the consequences of a foreign body response
such as inflammation, fibrosis, and loss of vasculature [20-22].
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Many researchers have modified the surface of the sensors to reduce
membrane biofouling in vivo. In an approach to reduce protein adsorption, Quinn
et al. [35] used poly(ethylene glycol) (PEG) in a polyhydroxyethylmethacrylate
(PHEMA)matrix. Since the PEG chains tend to stand up perpendicular to the
membrane surface, they provide a water-rich phase that resists binding of many
protein molecules. Vadgama’s et al. [36,37] reduced protein adsorption by using
diamond-like carbon, so-called “inert” materials. Shichiri et al. [38] incorporated
an alginate/polylysine gel layer at the sensor. Shaw et al. [39] reported
improvement in biocompatibility of a biosensor coated with PHEMA/PU
(polyurethane). Wilkins et al. [40] and Moussy et al. [7,41-43] introduced NafionTM
(perfluorosulphonic acid) membrane, to reduce “biofouling” on the surface of the
sensor and reduce interference from urate and ascorbate. Armour et al. [14]
coated their sensor tips with crosslinked albumin and Kerner et al. [44] developed
cellulose-coated sensors to improve sensor blood compatibility. However, none
of these approaches has been successful for long term, stable glucose
monitoring.
Collagen and its derived matrices are used extensively as natural
polymers in the biomedical field including tissue engineering due to its low
antigenicity, its biodegradability and its good mechanical, haemostatic and cellbinding properties [65-69]. In order to devise strategies for using collagen in the
development of advanced biomaterials for biomedical engineering, it is
necessary to confer mechanical strength and resistance to enzymatic
(collagenase) degradation resistance with chemical or physical crosslinking
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strategies. There are several strategies for crosslinking collagen-based
biomaterials. Glutaraldehyde (GA) is the most widely used as a crosslinking
agent for collagen-based biomaterials [65,75]. However, GA and its reaction
products are associated with cytotoxicity in vivo, due to the presence of
crosslinking byproducts and the release of GA-linked collagen peptides during
enzymatic degradation [77,78].
To avoid in vivo cytotoxicity and subsequent calcification of GAcrosslinked collagen, several alternative compounds have been examined as
potential collagen crosslinking agents [79,80] such as polyepoxy, hexamethylene
diisocyanate (HMDI), 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDC), and
ultra-violet (UV) or gamma-ray irradiation. Koob et al. [85-88] recently described
a process for crosslinking of type I collagen fibers with nordihydroguaiaretic acid
(NDGA), a plant compound with antioxidant properties. They showed that NDGA
significantly improved the mechanical properties of synthetic collagen fibers. In
addition, they showed that NDGA-crosslinked collagen fibers did not elicit a
foreign body response nor did they stimulate an immune reaction during six
weeks in vivo.
The extent of crosslinking and choice of crosslinking agent may also affect
the porosity and pore size of the scaffold and may greatly influence fibrous
capsule thickness, blood vessel density, and the location of vessels within the
three-dimensional porous scaffold [19]. Large pore scaffolds (greater than 60
micron pore size) allow deep penetration of capillaries and supporting
extracellular matrix (ECM). Sharkawy et al. [33] recently showed that after four
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weeks of subcutaneous implantation in rat, a well-organized collagen matrix
typical of a foreign-body response encapsulated non-porous implants, while the
porous polyvinyl alcohol (PVA) implants produced less fibrous and vascularized
tissue capsules.
The goal of this study was to develop a new porous collagen scaffold
around implantable glucose sensors for improving their biocompatibility. We
fabricated porous collagen scaffolds by using a freeze-drying method followed by
crosslinking using NDGA or GA. We evaluated the resistance of NDGA- and GAcrosslinked collagen scaffolds to degradation using both in vitro and in vivo
experiments. We also applied the scaffolds around a coil-type implantable
glucose sensor and measured sensor function in vitro.

24

2.2. Materials and Methods
2.2.1. Materials
Type I collagen (purified from fetal bovine tendon) was a generous gift
from Shriners Hospital for Children (Tampa, FL). Nordihydroguaiaretic acid
(NDGA) was purchased from Cayman Chemical Co. (Ann Arbor, MI). Glucose,
bovine serum albumin (BSA) and 50% (w/w) glutaraldehyde (GA) were obtained
from Fisher Scientific (Pittsburgh, PA). Glucose oxidase (GOD) (EC 1.1.3.4., type
X-S, Aspergillus niger, 157,500 U/g), epoxy adhesive (ATACS 5104),
polyurethane (PU), tetrahydrofuran (THF) and collagenase (EC 3.4.24.3, type I,
from Clostridium histolyticum, 302 U/mg) were obtained from Sigma-Aldrich (St.
Louis, MO). Sprague-Dawley out-bred rats (male, 375-399 g) were purchased
from Harlan (Dublin, VA).

2.2.2. Preparation and Crosslinking of Collagen Scaffolds
The collagen scaffolds were prepared by a freeze-drying method.
Collagen was dissolved in 3% acetic acid to prepare a 1% (w/v) solution. The
solution was applied to a cylinder-shaped polypropylene mold (Φ 10 mm, height
8 mm) and then freeze-dried. A cylindrical 3D porous scaffold was obtained. The
scaffolds were then crosslinked with NDGA or GA to minimize solubility and
improve resistance to collagenase degradation.
For NDGA crosslinking, dried collagen scaffolds were briefly soaked in
absolute ethanol, followed by soaking in 2 M of NaCl solution for 12 h at room
temperature. Scaffolds were re-suspended in oxygen sparged phosphate
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buffered saline (PBS, 0.1 M NaH2PO4, pH 9.0) for 30 min. at room temperature.
Scaffolds were then treated with 3 mg of NDGA in 1 mL of PBS as follow: NDGA
was dissolved in 0.4 N NaOH at a concentration of 30 mg/mL. One milliliter of the
NDGA solution was added directly to PBS in which the scaffolds were suspended
to a final concentration of 3 mg/mL. The scaffolds were agitated in the NDGA
solution for 24 h at room temperature. The scaffolds were removed, briefly rinsed
with water and freeze-dried.
For a comparative study of the effectiveness of the NDGA treatment, other
scaffolds were treated with 0.5% GA for 2 h or 12 h in ethanol solution at room
temperature. To prevent the dissolution or loss of the matrix during the GA
crosslinking process, we used 100% ethanol instead of water. The crosslinked
scaffolds were washed with de-ionized water and freeze-dried again. The
morphology of the scaffolds before/after crosslinking was examined using
scanning electron microscopy (SEM) after gold sputter coating of the samples in
a metal evaporator according to standard procedures.
To evaluate the stability of the scaffold after crosslinking, the degree of
crosslinking (Dc) was estimated by weighing the dried samples before and after
crosslinking. Dc was calculated using the following equation:

Dc [%] = (sample mass after crosslinking /
sample mass before crosslinking) × 100
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The swelling property of the porous scaffolds was examined by measuring
water absorption. The scaffolds were weighed after thorough drying (Wdry) and
immersed in purified water. After 24 h, the scaffolds were removed from the
water and immediately weighed again (Wwet). Water absorption was calculated by
using the following equation:

Water absorption (%) = [(Wwet – Wdry)/Wwet] × 100

2.2.3. In vitro and In vivo Evaluation of Collagen Scaffolds
To examine the biological stability of the crosslinked scaffolds, we
performed in vitro and in vivo biodegradation tests. In vitro biodegradation of
NDGA- and GA-crosslinked scaffolds was tested using bacterial collagenase.
Fabricated NDGA- and GA-crosslinked collagen scaffolds were incubated in the
collagenase solution (1 mg/mL in PBS at 37°C) for up to 4 weeks. Scaffolds were
removed from the solution, rinsed with de-ionized water and freeze-dried at given
time intervals (weeks 1 to 4) during incubation. The in vitro degradation was
evaluated as the percentage of weight difference of the dried scaffold before and
after enzyme digestion.
To determine the stability of the crosslinked scaffolds in vivo, we directly
implanted NDGA- and GA-crosslinked collagen scaffolds in rats. The scaffolds
were disinfected with 70% ethanol solution for 2 h and implanted subcutaneously
in the back of the rats. Scaffolds were explanted at 7, 14, 21, and 28 days after
implantation. After explantation, the scaffolds were examined macroscopically.
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2.2.4. Preparation of Porous Collagen Scaffolds around Implantable
Glucose Sensors
We first fabricated coil-type glucose sensors loaded with crosslinked
enzyme (GOD: Glucose Oxidase) using a Platinum-Iridium (Pt/Ir) wire (Teflon
coated, Φ 0.125 mm, Pt:Ir = 9:1, Medwire, Sigmund Cohn Corp.). Then, we
applied bovine tendon type I collagen scaffolds around the sensors [Fig. 2.1].
Briefly, in order to fabricate a glucose sensor, the Teflon coating of the top 10
mm of a Pt/Ir wire was removed and the wire was wound up along a 30-gauge
needle to form a coil-like cylinder. The cylinder unit had an outer diameter of 0.55
mm and an inner diameter of 0.3 mm and a length of 1 mm. A cotton thread was
inserted inside the coil chamber to retain the enzyme solution during enzyme
coating of the electrodes. GOD was added and crosslinked to the sensors by dip
coating in an aqueous solution containing 1% GOD, 4% BSA, and 0.6% (w/w)
glutaraldehyde. The outer membrane of the sensor was coated with EpoxyPolyurethane (Epoxy-PU) by dipping in Epoxy-PU solution (2.5% (w/v) in THF,
Epoxy:PU = 1:1). The sensor was dried at room temperature for at least 24 h.
The two ends of the sensing element were sealed by electrically-insulating
sealant (Brush-On electrical tape, North American Oil Company) [93,94].
To apply collagen scaffolds around the sensors, the sensors were dipcoated with 1% (w/v) collagen solution and freeze-dried. The porous scaffolds
around the glucose sensors were crosslinked with either NDGA or GA as
previously described. Obtained sensors were stored dry at room temperature or
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Figure 2.1.

Schematic Diagram of the Scaffold-coated Sensing Element of the
Glucose Electrode.
(1) Teflon-covered Pt-Ir wire;
(2) Ag/AgCl reference wire;
(3) Collagen scaffold;
(4) Electrically-insulating sealant;
(5) Epoxy-Pu outer membrane;
(6) Enzyme layer;
(7) Stripped and coiled Pt-Ir wire;
(8) Cotton fiber with GOD gel.
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in PBS at 4°C. The morphology of the sensors was observed using light
microscope and SEM. In addition, in order to evaluate sensitivity changes of the
sensors with varying wall thickness of the scaffold around the sensors, we
controlled the wall thickness of the scaffold by multiple dipping /freezing cycles in
collagen solution. The scaffold with the sensor was then freeze-dried and
crosslinked as previously described.
Silver wires (Teflon coated, Φ 0.125 mm, World Precision Instruments,
Inc.) were used to fabricate the Ag/AgCl reference electrodes. Silver wires were
coiled and anodized galvanostatically at 1mA overnight in stirred 0.1 M HCl
[93,94].

2.2.5. In vitro Characterization of Sensors Coated with Scaffolds
The glucose sensors were characterized in PBS (pH 7.4) at 700 mV
versus the incorporated Ag/AgCl reference electrodes. The working electrode
(Pt/Ir wire) and Ag/AgCl reference electrode of each sensor were connected to
an Apollo 4000 potentiostat (World Precision Instruments, Inc.). The background
current was allowed to stabilize for 10 min., and the sensors were then exposed
to a series of glucose solutions in order to examine their sensitivities and
linearities. The response sensitivity (S) was repeatedly assessed by 1)
measuring the response current (I1) of a C1 glucose solution, 2) adding a
concentrated glucose solution into the measured solution to increase the glucose
concentration to C2, and 3) measuring the response current (I2) of the resulting
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solution. The sensitivity was expressed as the current increase caused by a 1
mM glucose increase, i.e. S = (I2 - I1) / (C2-C1).
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2.3. Results and Discussion
2.3.1. Preparation of Porous Crosslinked Collagen Scaffolds
The chemistry of the NDGA crosslinking reaction differs from the reaction
using the GA treatment [Fig. 2.2]. GA is the most common crosslinking agent
used for fixation of collagen scaffolds for tissue bioengineering. Both aldehyde
functional groups of the GA molecule react with amine groups between two
neighboring polypeptide chains, particularly lysine side chains. Unfortunately, GA
crosslinking is encumbered with potential cytotoxicity problems caused by the
presence of unreacted residual groups or the release of monomers and small
polymers during enzymatic degradation [77,78].
NDGA treatment is an alternative crosslinking agent, which possesses
reactive catechols. Collagen crosslinking with NDGA mimics the quinine tanning
mechanism in the skate egg capsule. Catechol-quinone tanning systems are
prevalent in a wide variety of animals, which the process serves to strengthen
vulnerable extracellular matrices (e.g. insect cuticle, mussel byssus threads)
[85,95]. NDGA, isolated from the creosote bush, is a low molecular weight dicatechol containing two ortho-catechols. The two catechols on NDGA undergo
auto-oxidation at neutral or alkaline pH producing reactive quinones. Two
quinones then couple via aryloxy free radical formation and oxidative coupling,
forming bisquinone crosslinks at each end. The NDGA continues forming a large
crosslinked bisquinone polymer network in which the collagen fibrils are
embedded. The NDGA treatment does not form crosslinks with amino acid side
chains of collagen [85,86,95].
32

In this study, highly porous collagen scaffolds were prepared by a freezedrying method. We ascertained that the obtained scaffolds have an open cell and
interconnected pore structure based on SEM observation [Fig. 2.3(A)]. The pores
of the scaffolds are regularly distributed and range from 20 to 100 μm in diameter
(mean ~ 60 μm). Sharkawy et al. [33] reported that the a 60 μm mean-pore-sized
polyvinyl alcohol (PVA) sponge provided a tissue in-growth environment and
allows to infiltration of neovasculature but did not allow for fibrous tissue ingrowth. After crosslinking with NDGA and GA, the pore size and pore structure of
both scaffolds were not significantly altered [Fig. 2.3(B) and (C)].
Figure 2.4 shows the degree of crosslinking and water absorption of the
scaffolds using different crosslinking methods. The mass was reduced to about
70% after NDGA treatment and 60% for GA treatment after the crosslinking
process due to the loss of uncrosslinked collagen components. Crosslinked
collagen scaffolds had significantly higher form stability than uncrosslinked
collagen scaffolds. Also, the swelling behavior of NDGA- and GA-crosslinked
scaffolds showed no significant differences between the two different crosslinking
agents. The water absorptions of both crosslinked scaffolds were above 99%.
The high swelling property of sponge-like matrices seems to be dependent on
the porous inner structure of the scaffold, which possesses good absorbent
characteristics [96].

33

A
Collagen

N
HC

NH2

+
Glutharaldehyde O C
H

C
H

O
HC
N

+
NH2
Collagen

GA cross-linked Collagen

B
OH

CH3
HO

Oxidation

OH
CH3

HO

O

O
CH3

O

NDGA (di-catechol)

Di-quinone
O

O
O

Free Radical

O
O

Generation

*

Quinone

O

CH3

Oxidative

O

Coupling

O

O
O

O
Bisquinone

Collagen

Collagen

O
Collagen

O

O

Collagen

O

O

O O

O

O

O O
O

O

O O
O

O

O
O

O

NDGA cross-linked Collagen

Figure 2.2.

Schematic Mechanism for (A) GA and (B) NDGA Crosslinking of
the Collagen Scaffold.
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Figure 2.3.

C
C

SEM Morphology of the Collagen Scaffold. Determination of the
pore size of collagen scaffolds by SEM. (A) No crosslinking; (B)
GA-crosslinked; (C) NDGA-crosslinked.
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2.3.2. In vitro and In vivo Evaluation of Collagen Scaffolds
The biological stability of the crosslinked collagen scaffolds was
investigated by in vitro and in vivo biodegradation tests. Degradation in both
uncrosslinked (control) and crosslinked scaffolds was characterized by
determining weight loss of the scaffold after enzymatic digestion. The
uncrosslinked scaffolds and scaffolds crosslinked with GA for 2 hours were
completely degraded in the collagenase solution within several hours while
NDGA- or GA-crosslinked (for 12 h) scaffolds were not degraded within 24 hours.
A significant increase in resistance to enzymatic digestion could be shown after
crosslinking. Figure 2.5 shows long-term collagenase in vitro degradation test
(weight remaining %) of the NDGA- and GA-crosslinked scaffolds. After 1 week
exposure to collagenase, both types of scaffolds showed high resistance to
enzymatic digestion (> 80% weight remaining). After 3 and 4 weeks, all scaffolds
retained 70% of their initial mass. However, in the case of GA-crosslinked
scaffold, the pore size was increased after 4 weeks collagenase digestion
process [Fig. 2.6(B) vs Fig 2.6(D)]. In contrast, the pore size of NDGAcrosslinked scaffolds did not appear to increase [Fig. 2.6(A,C)]. As a result, we
suggest that NDGA or GA treatment can provide collagen scaffolds with
improved enzymatic biodegradation stability. The collagenase cleavage sites
were more effectively blocked by the crosslinking of the collagen scaffolds [97].
To study the stability of the crosslinked scaffolds in vivo, we implanted
crosslinked collagen scaffolds in the subcutaneous tissue of the Sprague-Dawley
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Figure 2.5.

Collagenase Resistance of GA- and NDGA-crosslinked Scaffold In
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treated with 0.5% GA for 12 h in ethanol solution at room
temperature.
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Figure 2.6.

A

B

C

D

SEM Morphology of the Scaffold after In vitro Degradation Study.
Results are shown as means ± SD (n=3). (A) NDGA-crosslinked
scaffold after 2 weeks collagenase treatment; (B) GA-crosslinked
scaffold after 2 weeks collagenase treatment; (C) NDGAcrosslinked scaffold after 4 weeks collagenase treatment; (D) GAcrosslinked scaffold after 4 weeks collagenase treatment.
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rats and explanted samples two and four weeks post implantation. After 2 weeks
implantation, the NDGA-crosslinked scaffolds did not show evidence of
degradation, but the overall shape of the GA-crosslinked scaffolds was deformed
and the size slightly reduced because of starting degradation [Fig. 2.7 (A)]. After
4 weeks, the size and shape of the GA-crosslinked scaffolds were dramatically
changed (-78% in size of 2 weeks)but there was a small change in the NDGAcrosslinked scaffolds (-18.9% in size of 2 weeks) [Fig. 2.7(B)]. This indicated that
the scaffolds treated with the NDGA were more stable than the scaffolds
crosslinked with the GA treatment used in these studies.

2.3.3. Porous Collagen Scaffolds around Implantable Glucose Sensors
We first fabricated coil-type glucose sensors loaded with crosslinked
enzyme (GOD: Glucose Oxidase) by using Platinum-Iridium (Pt/Ir) wires. Then,
we applied bovine tendon type I collagen scaffolds around the sensors [Fig. 2.1].
Yu et al. [94] previously reported that this “coil-type” sensor allows more GOD
loading, provides a larger electrochemical surface area, and therefore increases
the response current as compared to a “needle-type” sensor. Our sensor is
flexible and miniaturized (0.5 mm dia.) for subcutaneous implantation. It is
composed of a two-electrode system with a glucose indicating platinum electrode
and a Ag/AgCl reference-counter electrode. Our sensor utilizes a three-layer
membrane configuration of crosslinked collagen scaffold, epoxy-polyurethane
(Epoxy-PU) and GOD. The collagen scaffold (the outer layer in this case) can
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Subcutaneous Tissue. (A) 2 weeks after implantation; (B) 4 weeks
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uptake 99% of its dry weight of water including glucose and other molecules. The
Epoxy-PU membrane under the scaffold is permeable to glucose and oxygen but
impermeable to most interfering substances. GOD immobilized in a BSA/GA
matrix is sandwiched between the Pt/Ir wire and the Epoxy-PU membrane. In
order to eliminate air bubbles entrapped in the chamber during coating, to
stabilize the enzyme gel inside the chamber, and to make the enzyme solution
easier to remain in the coil, we used a cotton fiber inside the coil chamber. The
collagen scaffolds were prepared by a freeze-drying method and crosslinked to
minimize water solubility and enzymatic collagenase degradation. With a light
microscope, we confirmed that the porous scaffolds thoroughly surrounded the
sensor tips [Fig. 2.8(A) and (B)]. We also observed the surface and crosssectional morphology of the scaffolds around the sensors using SEM. Many
collagen fibrils and uniform open pore structure were observed on the surface
[Fig. 2.8(C)]. Inter-connected open pores in the scaffold and a thickness of 150 200 μm were observed in cross-sectional region [Fig. 2.8(D)].
The amperometric response curves of the glucose sensors with and
without scaffold (control) were obtained by varying the glucose concentration
from 5 mM to 15 mM as shown in Figure 2.9. These glucose concentrations were
selected because these concentrations were located in the linear response
region (2 - 30 mM) of the studied sensors. The results showed no significant
response current change before and after scaffold application around the sensor.
However, the sensors with scaffolds had a slower response time to reach
equilibrium current (T 95% ) than control sensors. The response time, T 95% , is
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Figure 2.8.

D

Light Microscope Pictures of the Implantable Glucose Sensing
Element and SEM Morphology of the Scaffold Region. (A)
Uncoated sensor; (B) Coated with scaffold; (C) Surface; (D) Crosssection.
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Figure 2.9.

Amperometric Response Curves of the Glucose Sensors from 5 to
15 mM Glucose Concentration. (1) Uncoated sensor; (2) Coated
with GA-crosslinked scaffold; (3) Coated with NDGA-crosslinked
scaffold. T95% is defined as the time at 95% of the maximum
current change (I15 mM - I5 mM).
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defined as the time at 95% of the maximum current change (I2 - I1). The T95% of
control sensor was 14.0 min. whereas T95% of the sensors with NDGA- and GAcrosslinked scaffold were 17.9 min. and 17.0 min., respectively. The delay of the
response time (17.9 and 17 min.) was probably caused by the added physical
barrier of the porous scaffolds.
The currents produced by sensors with NDGA-, GA-crosslinked scaffolds
and without scaffolds in response to varying glucose concentration (2 - 30 mM)
are showed in Figure 2.10. The response currents of the control sensors in the
high glucose concentration region (20 - 30 mM) were only a little higher than
those of the sensors with scaffolds. However, there was no statistical difference
between control and sensors with scaffolds (p > 0.05; student t-test). The
average sensitivity of the control, NDGA- and GA-crosslinked scaffold around
sensors was 11.0, 7.1, and 8.1 nA/mM, respectively. Therefore, scaffold
application around the glucose sensors did not negatively affect the function of
the sensors.
We also examined the sensitivity changes of the sensors with varying wall
thickness of the scaffold controlled by dipping cycles in collagen solution. As can
be seen in Figure 2.11, the sensitivity of the 4 times dip-coated sensors remained
at 60% of their initial sensitivity (no scaffold). When the sensors were dip-coated
more then 5 times, glucose could not diffuse properly through the scaffolds. The
sensitivity was dramatically reduced to below 20% of the initial sensitivity.
Although the porous scaffold material has good water absorbent properties, the
wall thickness can affect the sensor function.
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2.4. Conclusions
In this study, porous type I collagen scaffolds were prepared by a freezedrying method then crosslinked using NDGA- or GA treatments. The fabricated
collagen scaffolds have an open cell and interconnected pore structure. To allow
the infiltration neovasculature but to restrict fibrous tissue formation, the mean
pore size was controlled to 60 μm by controlling the concentration of the collagen
solution. Both crosslinking methods did not significantly affect the scaffolds
geometry and bulk properties. They also had a similar resistance property to the
collagenase enzyme in vitro. However, NDGA-crosslinked scaffolds were shown
to be more stable in vivo. In addition, we also applied the highly porous NDGAcrosslinked scaffolds to our implantable glucose sensor as a potential approach
for reducing “biofouling” and improving biocompatibility. The porous scaffold
application did not significantly affect the function of the glucose sensor.
Therefore, the application of an NDGA-crosslinked collagen scaffold might be a
good candidate for improving the biocompatibility of implantable biosensors. We
plan to use this scaffold to enhance the function and lifetime of implantable
biosensors by providing a controlled local environment around the sensors with
the additional help of various drugs and growth factors.
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CHAPTER 3
LONG-TERM IN VITRO / IN VIVO PERFORMANCE OF IMPLANTABLE
GLUCOSE SENSORS WITH CROSSLINKED COLLAGEN SCAFFOLDS

3.1. Introduction
Although many strategies for continuous glucose monitoring have been
developed over the past 30 years, achieving reliable and continuous glucose
monitoring in vivo is still a very difficult task. Very often, implantable glucose
sensors lose function after a relatively short period of time in vivo or become
unreliable, despite having excellent in vitro performances including good
selectivity, a high sensitivity, and a fast response time [33,62,98-100]. This loss
of function is in part a consequence of protein adsorption, inflammation, fibrosis
encapsulation, and loss of vasculature resulting from the biofouling and the
tissue trauma caused by the host response to the sensor and the surgical
implantation [20,21,48]. Ultimately, biofouling of the biosensor membrane very
much influences glucose diffusion, leading to in vivo sensor failures [101,102].
Overall, few successful long term implantations of glucose sensors have
been reported. Armour et al. [14] implanted 6 sensors intravascularly in dogs for
up to 108 days. Three sensors still functioned with no adherent clots and with the
same in vitro calibration curves before and after explantation. Updike et al. [103]
49

telemetrically monitored glucose using 3 implanted sensors. The sensor
response dropped during the initial period in vivo but then rose and stabilized
until 42-94 days. The same group (Gilligan et al. [104]) observed a stable foreign
body capsule (FBC) around the Dacron or ePTFE velour shells of their implanted
sensors. The sensors eventually failed because of enzymatic degradation or
biofouling of the sensor membranes. Pickup et al. [26] showed that only 50% of
sensors implanted in non-diabetic subjects responded in vivo. Explanted sensors
examined by scanning electron microscopy were coated by cells and proteins at
the sensor tip. Shichiri et al. [38] and Ertefai et al. [13] reported that the in vivo
lag time was increased, compared to the in vitro lag time. The increase was
attributed to protein deposition and FBC tissue at the sensor tip.
In order to minimize biofouling and to improve sensor function, many
researchers have designed new sensors with modifications to the surface of the
sensor outer membrane. Moussy et al. [41,42] introduced a new sensor with a
needle-type geometry and a Nafion outermost layer. Quinn et al. [35] used a
photo-crosslinkable copolymer containing 2-hydroxyethyl methacrylate (HEMA)
and poly(ethylene glycol) (PEG) as a sensor coating material. The results
showed that the copolymer-treated electrodes induced much less fibrous tissue
than control electrodes due to good biological performance of the PEG material.
In order to reproduce lipid characteristics to mimic the cell surface membranes,
and

induce

anti-thrombogenicity,

Nishida

et

al.

[105]

synthesized

a

phosphorylcholine (PC)-containing polymer which was applied as a sensor
membrane and showed excellent biocompatibility.
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Because of good swelling and viscoelastic properties and outstanding
biocompatibility, many researchers use hydrogels such as PEG hydrogel (Quinn
et al. [106]), phenylboronic acid-based hydrogel (Lei et al. [107]), and
polyacrylamide hydrogel (Fernandez et al. [108]) as the outermost coating of
glucose sensors. Recently, numerous strategies to control delivery of tissue
response modifiers (TRM) have been reported. For example, Gifford et al. [109]
used nitric oxide (NO) to downregulate mediators of the inflammatory response
and Norton et al. [110] characterized VEGF and dexamethasone (Dex) delivery
from sensor coatings.
We recently reported the development of new porous collagen scaffolds
which were applied around implantable glucose sensors to improve their
biocompatibility. We fabricated porous collagen scaffolds by using a freezedrying method followed by crosslinking using NDGA or GA [111].
In a continuation of this study, we evaluated the sensitivity of sensors with
ether NDGA- or GA-crosslinked collagen scaffolds during long-term in vitro and
in vivo experiments. We also fabricated two different lengths of sensors (long and
short wires) in order to minimize scaffold damage and compared their function in
vivo to evaluate the effects of micro-motion on the sensors.
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3.2. Materials and Methods
3.2.1. Materials
Type I collagen (purified from fetal bovine tendon) was a generous gift
from Dr. Thomas Koob, Shriners Hospital for Children (Tampa, FL).
Nordihydroguaiaretic acid (NDGA) was purchased from Cayman Chemical Co.
(Ann Arbor, MI). Glucose, bovine serum albumin (BSA) and 50% (w/w)
glutaraldehyde (GA) were obtained from Fisher Scientific (Pittsburgh, PA).
Glucose oxidase (GOD) (EC 1.1.3.4., type X-S, Aspergillus niger, 157,500 U/g),
epoxy adhesive (ATACS 5104), polyurethane (PU), and tetrahydrofuran (THF)
were obtained from Sigma-Aldrich (St. Louis, MO). Dextrose injection solution
(50%, w/v) was obtained from Abbott Laboratories (North Chicago, IL). The
FreeStyleTM portable glucometer was from TheraSense (Alameda, CA). SpragueDawley out-bred rats (male, 375-399 g) were purchased from Harlan (Dublin, VA).

3.2.2. Preparation of Porous Collagen Scaffolds around Implantable
Glucose Sensors
We

fabricated

miniature

coil-type

glucose

sensors

loaded

with

crosslinked enzyme (GOD: glucose oxidase) using a platinum-iridium (Pt/Ir) wire
(Teflon coated, Φ 0.125 mm, Pt:Ir = 9:1, Medwire, Sigmund Cohn Corp., Mount
Vernon, NY). We applied bovine tendon type I collagen scaffolds around the
sensors. Scaffolds were then crosslinked with NDGA or GA treatment as
previously described [111] to minimize solubility and to improve resistance to
enzymatic degradation in vivo. Control sensors (without scaffolds) and sensors
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with NDGA- or GA-crosslinked scaffolds were equilibrated in phosphate-buffered
saline (PBS, 0.1 M NaH2PO4, pH 9.0) for 2 days at room temperature prior to
being used in vitro or in vivo.
The initial sensitivity of all sensors was measured in 5 and 15 mM
glucose in PBS. Amperometric measurements were performed at room
temperature at 0.7 V vs Ag/AgCl. The working electrode (Pt/Ir wire) and the
Ag/AgCl reference electrode of each sensor were connected to an Apollo 4000
potentiostat (World Precision Instruments, Inc., Sarasota, FL).
In order to investigate the effect of wire length on the sensor function, we
fabricated sensors with two different lengths; 10 and 30 mm [Fig 3.1]. Only the
wires were of different length, the sensing elements remained identical.

3.2.3. Long-term In vitro Characterization of Sensors Coated with Scaffolds
In order to examine the long-term in vitro sensitivity of sensors, uncoated
(control) sensors, sensors with NDGA-crosslinked collagen scaffolds and
sensors with GA-crosslinked collagen scaffolds (n=8 / group) were incubated in
PBS at 37°C for 4 weeks. At 7, 14, 21, and 28 days, each sensor was removed
and tested in glucose solution.
The sensitivity of the glucose sensors was characterized in glucose/PBS
(pH 7.4) at 700 mV versus the incorporated Ag/AgCl reference electrodes. The
background current was allowed to stabilize for 10 min., and the sensors were
then exposed to a series of glucose solutions in order to examine their
sensitivities and linearities.
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A

B

Figure 3.1.

Photograph Showing (A) Long Wire and (B) Short Wire Collagen
Scaffold-coated Glucose Sensors.
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The response sensitivity (S) was repeatedly assessed by 1) measuring the
response current (I1) of a C1 glucose solution, 2) adding a concentrated glucose
solution into the measured solution to increase the glucose concentration to C2
and 3) measuring the response current (I2) of the resulting solution. The
sensitivity was expressed as the current increase caused by a 1 mM glucose
increase, i.e. S = (I2 - I1) / (C2-C1).

3.2.4. Implantation Procedures
All implantable glucose sensors were disinfected using 70% ethanol and
then placed in sterile PBS prior to implantation. During the surgical procedure, a
continuous flow gas anesthesia system was used to deliver 1.5 % isoflurane to
the rats in 2.0 L/min. oxygen flow. All protocols were approved by the University
of South Florida Institutional Animal Care and Use Committee (IACUC). Fortyeight sensors (eight control short sensors; CS, eight control long sensors; CL,
eight NDGA-crosslinked scaffold around short sensors; NS, eight NDGAcrosslinked scaffold around long sensors; NL, eight GA-crosslinked scaffold
around short sensors; GS, and eight GA-crosslinked scaffold around long
sensors; GL) were implanted subcutaneously on the back of the rats. Each rat
received two of one type of sensors.
For long sensors, two 1.5 cm long longitudinal incisions were made 1.5
cm laterally to the dorsal midline, and 3-4 cm caudally from the neck. A
subcutaneous pocket was created using blunt surgical scissors. A 14 ga. I.V.
catheter was inserted subcutaneously toward the incision from the 4-5 cm lower
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back region. The needle was withdrawn leaving the cannula in the subcutaneous
tissue. The sensor wires were carefully fed into the cannula through the incision
[Fig. 3.2(A)]. The sensor was secured to the skin by passing a 3-0 Prolene suture
through the small gap of the wound clip covering the sensor wires and incisions
closed using 3-0 Prolene. The cannula was then withdrawn, leaving the sensor in
the subcutaneous tissue.
For short sensors, same-sized incisions were made and a subcutaneous
pocket was also created using blunt surgical scissors before implantation.
However, the sensors were directly implanted through the incision without using
a cannula [Fig. 3.2(B)]. The sensors were secured to the skin and incisions
closed using the same approach utilized for the long sensors.
In addition, in order to evaluate the inflammatory response of the tissue
around and cellular intrusion into the collagen scaffolds, we directly implanted
NDGA- and GA-crosslinked scaffolds (without sensors) in the rats. At set time
intervals, tissue samples containing the scaffolds were excised and embedded in
paraffin. Sections (5 μm in thickness) were cut and stained with Mayers
hematoxylin and eosin (H&E) stain. Stained sections were analyzed and
photographed using an Olympus BX41 microscope (Olympus; Tokyo, Japan).

3.2.5. Long-term In vivo Evaluation of Sensors Coated with Scaffolds
The sensitivity of each sensor was measured every seven days for up to
28 days or until there was no amperometric response from the implanted sensor.
During each measurement period, four rats were anesthetized using isoflurane
56

Figure 3.2.

Surgical Procedures by Two Different Implantation Techniques for
Long Wire Sensors and Short Wire Sensors. (A) Long wire sensor
(using a 14 ga. catheter guidance); (B) Short wire sensors (direct
implantation).

57

and the eight implanted sensors were continuously monitored using two Apollo
4000 potentiostats. After a stable signal was obtained from the sensors, 0.7 mL
of sterile 50% dextrose was administered intraperitoneally using a 27 ga. needle.
Following the injection, small blood samples were collected every 7 minutes from
the rat tail and the glucose level was determined using the standard FreestyleTM
glucometer. The amperometric response corresponding to the glycemia of the rat
was recorded at the corresponding current-time intervals of each sensor. The
sensor sensitivity was calculated by dividing the change in current (I) by the
change in glycemia (C) between the initial (before dextrose injection) and the
peak status (after dextrose injection) as follows: Sensitivity (nA/mM) = (Imax – I0) /
(Cmax – C0)

58

3.3. Results and Discussion
3.3.1. Preparation of Implantable Glucose Sensors with Porous Crosslinked
Collagen Scaffolds
In order to create a porous scaffold for implantable glucose sensors, we
first fabricated coil-type glucose sensors loaded with crosslinked enzyme (GOD:
glucose oxidase) using platinum-iridium (Pt/Ir) wires. Then, we applied bovine
tendon type I collagen scaffolds around the sensors. The collagen scaffolds were
prepared by a freeze-drying method and crosslinked using NDGA or GA
treatment to minimize their aqueous solubility and reduce their degradation in
vivo. With a light microscope, we confirmed that the porous scaffolds thoroughly
surrounded the working electrodes [Fig. 3.3]. Both scaffolds were semitransparent in aqueous solution. GA-crosslinked scaffolds appeared white, while
the NDGA-crosslinked scaffolds were brown. We also observed high swelling for
both scaffolds around the sensors in aqueous solution. We reported previously
[111] that these sponge-like matrices with porous inner structure could absorb
water above 99%, thus allowing glucose to diffuse freely.
Figure 3.4 shows a schematic of a fully assembled coil-type glucose
sensor with a scaffold ready for implantation. The newly assembled sensor is
composed of a two-electrode system with a glucose indicating working Pt/Ir
electrode and an Ag/AgCl reference-counter electrode. We added a loop
between the two electrode coils to avoid micro-shorting caused by the two
electrodes touching each other. A surgical wound clip was applied to provide a

59

Figure 3.3.

Photographs of Implantable Sensors Coated with (A) GAcrosslinked Porous Collagen Scaffold and (B) NDGA-crosslinked
Porous Collagen Scaffold.

60

2

1

5
4
4

3

Implanted Part
Outside
Skin

Figure 3.4.

Schematic of Short Wire Implantable Glucose Sensor.
(1) Pt/Ir working electrode with scaffold;
(2) Ag/AgCl reference electrode;
(3) Loop to protect micro-motion and micro-short by two
electrodes contact;
(4) Wires twisted together
(5) Wound clip
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suturing site during the implantation procedure and to prevent the sensor moving
out of the skin (i.e. for anchoring).

3.3.2. Long-term In vitro Evaluation of Sensors with Porous Collagen
Scaffolds
The long-term in vitro function of the sensors was determined by tracking
their sensitivity for up to 4 weeks. Control sensors (without scaffold), and sensors
with NDGA- or GA-crosslinked scaffolds were incubated in PBS at 37°C for up to
4 weeks. The sensors were removed from the PBS at weekly intervals and their
sensitivity was determined. The pre-incubation sensitivity (week 0) was
measured at the beginning of the in vitro study and the percentage of sensitivity
change was calculated from the ratio of the sensitivity of the sensors at given
time interval to the pre-incubation sensitivity. The sensitivity of all sensors was
tested in 5 and 15 mM glucose/PBS. Figure 3.5 shows the sensitivity change of
all sensors over 4 weeks. We observed a slight decrease of the sensitivity of
sensors with either NDGA- or GA-crosslinked scaffolds, compared to the control
(no scaffold) sensors after 1 week incubation. After 2 weeks, the sensitivities of
all sensors increased to a level higher than their original sensitivity, probably
because of an increase in epoxy-PU membrane permeability due to progressive
membrane swelling in aqueous solution. After 2 weeks, the sensitivity of the
control sensors, as well as sensors with either NDGA- or GA-crosslinked
scaffolds, steadily decreased, however, all sensors retained above 80% of their
original sensitivity up to 4 weeks. We believe that the sensitivity decrease after
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Figure 3.5.

Long-term In vitro Sensitivity Changes of Control Sensors and
Sensors with NDGA- or GA-crosslinked Collagen Scaffolds. Results
are shown as means ± SD.
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2 weeks may be caused by progressive loss of enzyme activity. Both NDGA and
GA-crosslinked scaffolds were still intact around the sensors at week 4. There
was no detection of any deformation or detachment of the scaffolds from the
sensor membrane surface. Although the overall trend of the sensitivity of the
sensors with scaffolds was lower than with the control sensors, the application of
scaffolds around sensors did not critically affect the function of the sensors
during the 4 week in vitro study.

3.3.3. Long-term In vivo Performance of Sensors with Porous Collagen
Scaffolds
In this study, 48 sensors including control sensors (short/long, CS/CL),
and sensors with NDGA- or GA-crosslinked scaffolds (short/long, NS, NL, GS,
GL), were implanted subcutaneously in the back of 24 Sprague-Dawley out bred
rats for a period of 4 weeks. The in vivo sensitivity of every sensor was measured
at week 1, 2, 3, and 4. The pre-implantation sensitivity of all sensors was tested
using 5 mM and 15 mM glucose/PBS just before implantation. Figure 3.6 shows
a photograph of the in vivo continuous glucose monitoring procedure with the
anesthetized rats. A maximum of 8 sensors were connected to two 4 channels
potentiostats. The current produced by the sensors versus time (black arrow)
was displayed on two monitors. After reaching a stable signal for 1 – 2 hr,
glucose was administered intraperitoneally. Small amounts of blood were
sampled every 7 minutes from the rat tail and glucose level was determined
using a standard portable glucometer (white arrow).
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Figure 3.6.

Photograph of In vivo Continuous Glucose Monitoring Procedure.
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The percentage of sensitivity change for each sensor during the 4 week
study is shown in Figure 3.7. From this figure, a few initial observations can be
made: 1) The sensitivity of all sensors dramatically decreased after implantation
compared to the pre-implantation values. This was probably due to tissue
damage which occurred during surgical procedures and the subsequent host
response including protein adsorption, blood clot, and the infiltration of
inflammatory cells and other cells (e.g. fibroblasts) around the sensor tips [112].
2) As for the in vitro study, the control sensors retained a higher sensitivity than
the sensors with scaffolds. The sensors with NDGA-crosslinked collagen
scaffolds also had a higher sensitivity than the sensors with GA-crosslinked
scaffolds. 3) The sensitivity of the short sensors (CS, NS, GS) appeared to be
slightly greater than the sensitivity of the long sensors.
Table 3.1 shows the number of working sensors (used in Figure 3.7) at
given time intervals. Initially, 3 sensors did not work at week 1 but regained their
function at week 2. Both CS and CL sensors had a higher sensor survival rate (4
out of 8, 6 out of 8, respectively) in vivo 4 weeks post implantation than sensors
with scaffold coatings. The use of scaffolds worsened the survival rate of the
sensors. However, the short sensors had a higher survival rate than the long
sensors at 4 weeks post implantation (CL-4, NL-2, GL-1 vs CS-6, NS-4, GS-4).
We believe that this might result from the long sensors having greater range of
motion when the animals move than the short sensors.
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Figure 3.7.

Long-term In vivo Sensitivity Changes of Control Sensors and
Sensors with NDGA- or GA-crosslinked Scaffold. Results are
shown as means ± SD. (control short; CS, control long; CL, NDGAcrosslinked scaffold around short sensors; NS, NDGA-crosslinked
scaffold around long sensors; NL, GA-crosslinked scaffold around
short sensors; GS, GA-crosslinked scaffold around long sensors;
GL)
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Table 3.1.

Number of Working Sensors after Implantation. (# out of 8).
Weeks after implantation

Scaffolds
Control (no scaffold)

Wire

1

2

3

4

Long

8

7

4

4

Short

7

8

7

6

Long

2

3

2

2

Short

8

5

5

4

Long

2

2

1

1

Shot

5

6

6

4

NDGA-crosslinked

GA-crosslinked
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The larger macro-/micro-motion may have caused more tissue and
scaffold damage. We observed scaffold detached from the working electrode of
the long NL sensors [Fig. 3.8(A)], while the NDGA-crosslinked scaffold around
the short sensor NS remained in a stable position [Fig. 3.8(B)]. Regarding the
GA-crosslinked scaffolds, we could not detect any such scaffold around both long
and short sensors [Fig. 3.8(C) and (D)]. This is consistent with our previous study
where we observed that the size and shape of the GA-crosslinked scaffolds were
dramatically changed (degraded) after 4 weeks of implantation, while the NDGAcrosslinked scaffolds remained mostly intact.
In order to evaluate inflammatory response of the tissue around and
within the collagen scaffolds, we directly implanted NDGA- and GA-crosslinked
scaffolds (without sensors) in the rats for up to 4 weeks. After 2 weeks
implantation, H&E staining revealed the presence of many inflammatory cells
including polymorphonuclear (PMN) cells, monocytes, and macrophages within
and around the GA-crosslinked scaffolds [Fig. 3.9(A)]. However, for the NDGAcrosslinked scaffolds, few inflammatory cells were observed around the scaffolds,
and there was no infiltration of cells in the center region of the scaffolds [Fig.
3.9(B)]. Week 4 showed infiltration of inflammatory cells and fibroblasts, along
with granulation tissue deposition inside the pore of the GA-crosslinked scaffolds
[Fig. 3.9(C)], and again, less inflammation within and around the NDGAcrosslinked scaffolds [Fig. 3.9(D)]. This result shows that the NDGA-crosslinked
collagen scaffolds are more biocompatible than the GA-crosslinked collagen
scaffolds and is consistent with a report by Koob et al. [85] showing that NDGA69
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Figure 3.8.

Representative Photograph of Scaffolds In situ after 4 Weeks Post
Implantation. (A) Long sensor with NDGA-crosslinked scaffold; (B)
Short sensor with NDGA-crosslinked scaffold; (C) Long sensor with
GA-crosslinked scaffold; (D) Short sensor with GA-crosslinked
scaffold.
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Figure 3.9.

Hematoxylin and Eosin Stained Sections Showing Tissue
Surrounding Porous Scaffolds. (A) GA- and (B) NDGA-crosslinked
scaffold and after 2 weeks post implantation; (C) GA-and (D)
NDGA-crosslinked scaffold after 4 weeks post implantation. (T tissue surrounding scaffold, SC - scaffold, BV - blood vessels)
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crosslinked collagen fibers appeared intact with little foreign body response after
implantation in rabbits. The size of the GA-crosslinked scaffolds was reduced
and the pore structure was deformed as the implantation time increased. We also
found neovasculature in both scaffolds after 4 weeks post-implantation [Fig.
3.9(C) and (D), arrows].
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3.4. Conclusions
In this study, we applied porous type I collagen scaffolds around
implantable glucose sensors by a freeze-drying method and then crosslinked the
scaffolds using NDGA or GA treatments. The fabricated collagen scaffolds had
an open cell and interconnected pore structure. All sensors including control
sensors (without scaffold), and sensors with NDGA- or GA-crosslinked scaffolds
remained functional during the 4 week in vitro study. The application of both
types of scaffolds around the sensors did not critically affect the function of these
sensors in vitro.
In the 4 weeks in vivo study, the sensitivity of all sensors dramatically
decreased (30 – 60%) after 1 week of implantation and then remained relatively
stable. The sensitivity and survival rate of the short sensors were higher than the
sensitivity of the long sensors possibly as a result of reduced motion within the
animals. The sensors with NDGA-crosslinked scaffolds had a higher survival and
sensitivity than the sensors with GA-crosslinked scaffolds. By histological
examination, we confirmed that the NDGA-crosslinked scaffolds are more
biocompatible than the GA-crosslinked scaffolds.
Therefore, this study shows that an NDGA-crosslinked collagen scaffold
can be incorporated into the design of our implantable glucose sensor. However,
the control sensors (no scaffolds) performed better than the sensors with
scaffolds. The scaffolds alone did not improve the function and lifetime of our
implantable glucose sensor. This indicates that in order to use these scaffolds as
a way to control the local tissue environment around implanted sensors and thus
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improve their function and lifetime we still need to improve the scaffolds. This
could potentially be achieved by using the NDGA-crosslinked collagen scaffold to
also deliver various drugs and growth factors to modify the tissue response to the
sensors.
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CHAPTER 4
DEXAMETHASONE-LOADED PLGA MICROSPHERES/COLLAGEN
SCAFFOLD COMPOSITE SYSTEM FOR IMPLANTABLE
GLUCOSE SENSORS

4.1. Introduction
Although miniaturized implantable glucose sensors show excellent
performance in vitro, they tend to become unreliable and lose their function after
prolonged exposure to the in vivo environment, due to the foreign body response
(i.e. inflammation, fibrosis, and loss of vasculature) [20,21,48,62,98]. In particular,
the accumulation of inflammatory cells and dense fibrotic tissue around the
sensor hampers the diffusion of glucose from the capillaries to the sensors
[103,113-115]. Despite numerous studies using sensors of several different types,
there are no long-term implantable glucose sensors commercially available
[62,116].
In order to improve the function of implantable glucose sensors,
dexamethasone (Dex, an anti-inflammatory agent) has been used to control the
tissue reactions to implanted devices. Dex, a synthetic glucocorticoid, is widely
used to suppress inflammatory reactions caused from radiant, mechanical,
chemical, infectious and immunological stimuli [50,110,117,118]. It inhibits the
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production of critical factors involved in the inflammatory response such as
vasoactive/ chemoattractive factors and lipolytic/proteolytic enzymes [50]. Patil et
al. [53] prepared Dex-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres/
poly(vinyl alcohol) (PVA) hydrogel composite coatings for implantable biosensors
to control detrimental tissue reactions and fibrosis at the sensor/tissue interface.
Norton et al. [52,110] reported that they fabricated hydrogel (copolymer; 2hydroxy-ethyly methacrylate, N-vinyl pyrrolidinon, and polyethylene glycol)
sensor coatings containing Dex and/or vascular endothelial growth factor (VEGF)
to minimize the foreign body response and to promote angiogenesis. Klueh et al.
[62,63] induced significant neovascularization surrounding an implanted sensor
using a VEGF-cell-fibrin gene transfer system. Kim and Martin [119] investigated
a composite of Dex-loaded PLGA nanoparticles/alginate hydrogel for neural
prosthetic application. Lincoff et al. [47] developed a Dex eluting stent using a
high molecular weight poly-L-lactic acid (PLLA) biodegradable polymer
containing the drug to prevent restenosis. Gomez-Gaete et al. [120] optimized
the encapsulation of Dex in PLGA nanoparticles for ocular delivery.
The use of Dex-loaded microspheres/nanospheres to provide controlled
local drug delivery are typically prepared using a synthetic biodegradable
polymers such as PLGA and PLLA [49]. The degradation rate of these polymers
in vitro/in vivo can be controlled by regulating the composition of monomer units
(i.e. lactic acid and glycolic acid). Thus, PLGA microspheres, which have
controllable drug release kinetics, have been utilized not only for Dex delivery but
also for angiogenic growth factors and other proteins delivery [61,121-123]. Both
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PLGA and PLLA are also widely used for tissue engineering [124,125] and gene
therapy [126] research due to their good biocompatibility and suitable
biodegradability characteristics [124-126].
Due to good swelling and viscoelastic properties and outstanding
biocompatibility, hydrogels have also been used as sustained-release drug
delivery systems and as the outermost coatings of implantable glucose sensors.
Pluronics [127-129], also called Poloxamers, are particularly interesting because
they are in a sol state below a lower critical solution temperature (LCST; i.e.,
reverse sol-gel transition temperature, 4-20°C), but transition to a gel state above
37°C [130,131]. Oh et al. [132] fabricated a temperature-controllable crosslinked
Pluronic/alginate mixture for use in delivering a non-steroidal anti-inflammatory
drug (NSAID) for prevention of post-surgical tissue adhesion.
In this study, we first fabricated porous collagen scaffolds around
implantable glucose sensors using a freeze-drying method, followed by
crosslinking the collagen scaffold using NDGA treatment [111]. In order to
minimize the inflammatory response to the sensors, we then added Dex-loaded
microspheres

to

the

scaffold

by

dipping

the

sensor/scaffold

in

a

microspheres/Pluronic F127 hydrogel suspension. We characterized the sensors
with the Dex-loaded microspheres/ scaffold composite system in vitro and then
tested these sensors in rats.
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4.2. Materials and Methods
4.2.1. Materials
Poly(DL-lactide-co-glycolide) (PLGA, Resomer RG503H, 50:50) was a
generous gifted from Boehringer-Ingelheim (Germany). Type I collagen (purified
from fetal bovine tendon) was a generous gift from Dr. Thomas Koob, Shriners
Hospital for Children (Tampa, FL). Nordihydroguaiaretic acid (NDGA) was
purchased from Cayman Chemical Co. (Ann Arbor, MI). Methylene chloride
(HPLC-GC/MS grade), acetonitrile (HPLC grade), methanol (HPLC grade),
glucose, bovine serum albumin (BSA) and 50% (w/w) glutaraldehyde (GA) were
obtained from Fisher Scientific (Pittsburgh, PA). Polyvinyl alcohol (PVA; avg. mol.
wt = 30,000 - 70,000), dexamethasone (Dex, C22H29FO5; Fw = 392.5), Pluronic
F-127, glucose oxidase (GOD) (EC 1.1.3.4., type X-S, Aspergillus niger, 157,500
U/g), epoxy adhesive (ATACS 5104), polyurethane (PU), acetone, and
tetrahydrofuran (THF) were obtained from Sigma-Aldrich (St. Louis, MO).
Dextrose injection solution (50%, w/v) was obtained from Abbott Laboratories
(North Chicago, IL). The FreeStyleTM glucometer was from TheraSense
(Alameda, CA). Sprague-Dawley out-bred rats (male, 375-399 g) were
purchased from Harlan (Dublin, VA).

4.2.2. Preparation of Dex-loaded Microspheres
Biodegradable PLGA microspheres loaded with Dex were prepared by an
oil-in-water (O/W) emulsion/solvent evaporation technique. The oil phase
consisted of 80 mg of PLGA and 50 mg of Dex dissolved in 6 mL of a mixture of
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either 5:1 methylene chloride to methanol or 5:1 methylene chloride to acetone.
This oil phase was added to 100 mL of 0.2% PVA in water, which was stirred
with an overhead stirrer at 800 RPM for 30 min. to achieve an O/W emulsion
system. The resulting emulsion was stirred on a magnetic stir plate for 16 h to
allow complete evaporation of the solvent and solidification of the droplets into
microspheres. During the emulsion and solidification process, aluminum foil was
completely surrounded the beaker to protect from UV light (UV light will degrade
Dex). The microspheres were collected by centrifugation at 8,000 RPM (7,500x
g) for 15 min. in a refrigerated centrifuge set at 15°C. The microspheres were
washed 5 times with deionized water. The centrifuge tubes were capped and
placed in freezer (-20°C) overnight. The tubes were covered with aluminum foil
and were placed in a Freeze-drying system overnight to obtain dry microspheres.

4.2.3. Microsphere Analysis
The Dex loading efficiency and encapsulation efficiency into microspheres
were determined using high performance liquid chromatography (HPLC) (LC10AT vp; SPD-10A vp; SCL-10A vp; Shimadzu, Japan). Microspheres (10 mg)
were dissolved in 1 mL of acetonitrile. Dex concentration in dissolved samples
was determined by HPLC analysis at 246 nm using a Premier C-18 column
(Shimadzu, Japan) with a mobile phase of acetonitrile and water mixture (42:58),
with flowing mobile phase at 1 mL/min.
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The drug loading efficiency was calculated using the following equation:

Loading efficiency (%) = mg of Dex / 10 mg of microspheres x 100

The drug encapsulation efficiency was determined using the following equation
[133]:

Encapsulation efficiency (%) = experimental drug loading /
theoretical drug loading x 100

The morphology of the microspheres was examined using scanning
electron microscopy (SEM) after gold sputter coating of the samples in a metal
evaporator according to standard procedures.

4.2.4. Preparation of Dex-loaded Microspheres/Scaffold Composite System
Collagen scaffolds were prepared by a freeze-drying method. Collagen
was dissolved in 3% acetic acid to prepare a 1% (w/v) solution. The solution was
applied to a cylinder-shaped polypropylene mold (Φ 10 mm, height 8 mm) and
then freeze-dried. The scaffolds were then crosslinked with NDGA treatment as
follow. Dried collagen scaffolds were briefly soaked in absolute ethanol, followed
by soaking in 2 M NaCl in water for 12 h at room temperature. Scaffolds were
resuspended in oxygen sparged phosphate buffered saline (PBS, 0.1 M
NaH2PO4, pH 9.0) for 30 min. at room temperature. Scaffolds were then treated
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with 3 mg NDGA/mL of PBS prepared as follows: NDGA was dissolved in 0.4 N
NaOH at a concentration of 30 mg/mL. One milliliter of the NDGA solution was
added directly to 9 mL of PBS containing the scaffold. The scaffolds were
agitated in the NDGA solution for 24 h at room temperature. The scaffolds were
removed, briefly rinsed with water and freeze-dried.
The microspheres containing Dex were incorporated into the NDGAcrosslinked collagen scaffold by dipping the scaffolds in a microsphere
suspensions. Two different microsphere suspension solution (hydrogel and
water) were used for fabrication of microsphere/scaffold composites. Pluronic F127 was adopted as the hydrogel material, using a 25% solution with selfaggregation properties at low critical solution temperature (LCST; i.e., reverse
sol-gel transition temperature, 4-20°C) [130-132]. Pluronic solution, freshly
prepared by dissolving in deionized water, was kept in the refrigerator (4°C ) prior
to use. Five, 10, 20 and 40 mg/mL of microspheres, loaded with Dex, were
dispersed in the Pluronic solution. Dried scaffolds were soaked in the hydrogel
suspension with vortex mixing to incorporate the microspheres evenly. During the
procedure, the suspensions were kept in an ice bath to prevent the gelation of
Pluronic

F-127.

After

completion

of

the

loading

procedure,

the

microspheres/scaffolds were taken out of the microspheres-hydrogel suspension
solution and then placed at room temperature to allow gel formation. Another
group of scaffolds were prepared using 5, 10, 20 and 40 mg/mL of microsphereswater suspension at room temperature. In this case, no hydrogel was used. The
loading efficiency of Dex in the scaffolds was determined using HPLC as
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previously described above. Drug concentration was standardized by dividing by
total mass of the scaffold including microspheres.

4.2.5. In vitro Release of Dex from the Microspheres/Scaffold Composite
System
The in vitro release study was performed in phosphate buffered saline
(PBS) under sink conditions. Samples (1.5 - 2.5 mg) of Dex-loaded
microspheres/scaffold composites were incubated in 1 mL of PBS on a heated
rocker (Barnstead Lab-Line, US) at a constant temperature (37°C) over 21 days.
For comparison, 10 mg of standard Dex-loaded PLGA microspheres were
incubated under the same conditions. At 3 or 7 day time intervals, 0.5 mL of
supernatant was taken for analysis and replaced with 0.5 mL of fresh PBS into
the test tube. Dex concentration of in the samples was determined by HPLC, as
described above.

4.2.6. Preparation of Implantable Glucose Sensors with Microspheres/
Scaffold Composite System
We first prepared coil-type glucose sensors loaded with crosslinked
enzyme (GOD: glucose oxidase) using a platinum-iridium (Pt/Ir) wire (Teflon
coated, Φ 0.125 mm, Pt:Ir = 9:1, Medwire, Sigmund Cohn Corp.). Bovine tendon
type I collagen scaffolds were fabricated around the sensors and crosslinked with
NDGA as previously described [111].
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In order to incorporate microspheres loaded with Dex into the scaffolds,
the sensors with scaffolds were soaked in either the microsphere-hydrogel
suspension or the microsphere-water suspension with vortex mixing as described
above. The sensitivities of the sensors (with collagen scaffold only; and with
collagen scaffold plus microspheres) were determined in 5 mM and 15 mM
glucose/PBS using an Apollo 4000 potentiostat (World Precision Instruments,
Inc., Sarasota, FL). Amperometric measurements were performed at room
temperature at 0.7 V vs Ag/AgCl. The response sensitivity (S) was assessed by
1) measuring the response current (I1) of a glucose solution (C1), 2) adding a
concentrated glucose solution into the measured solution to increase the glucose
concentration (C2), and 3) measuring the response current (I2) of the resulting
solution. The sensitivity was expressed as the current increase caused by a 1
mM glucose increase, i.e. S = (I2 - I1) / (C2-C1).

4.2.7. Implantation Procedures
All implantation protocols were approved by the University of South
Florida Institutional Animal Care and Use Committee (IACUC). All implantable
glucose sensors were prepared aseptically and then placed in sterile Petri dishes
under humidified conditions to prevent the hydrogel from drying. During the
surgical procedure, a continuous flow gas anesthesia system was used to deliver
1.5 % isoflurane to the rats in a 2.0 L/min. oxygen flow.
Eight sensors (with microspheres/hydrogel/NDGA-crosslinked collagen
scaffold) were implanted subcutaneously on the back of the rats as follows. Two
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sensors were implanted per rat. Two 1.5 cm long longitudinal incisions were
made 1.5 cm laterally to the dorsal midline and 3-4 cm caudally from the neck. A
subcutaneous pocket was created using blunt surgical scissors before
implantation. The sensors were directly implanted through the incision. The
sensors were secured to the skin and the incision was closed using 3-0 Prolene.
In addition, in order to evaluate the inflammatory response to the collagen
scaffolds without the influence of the sensor, we directly implanted microspheres/
scaffold samples (without sensors) in the rats. At set time intervals, tissue
samples including scaffolds were embedded in paraffin. Sections (ca. 5 μm in
thickness) were cut and stained with Mayers hematoxylin and eosin (H&E) stain.
Stained sections were analyzed and photographed using an Olympus BX41
microscope (Olympus; Tokyo, Japan).

4.2.8. In vivo Evaluation of Sensors Coated with Microspheres/Scaffold
Composite System
The sensitivity of implanted sensors was measured every seven days for
up to 28 days or until there was no amperometric response from the implanted
sensors. During each measurement period, four rats were anesthetized using
isofluorane and the eight implanted sensors were continuously monitored using
two Apollo 4000 potentiostats. After a stable signal was obtained from the
sensors, 0.7 mL of sterile 50% dextrose was administered intraperitoneally using
a 27 ga. needle. Following the injection, small blood samples (~ 5 μL) were
collected every 7 min. from the rat tail, applied to test strips and the glucose level
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was determined using the standard FreestyleTM glucometer. The amperometric
response corresponding to the glycemia of the rat was recorded at the
corresponding current-time intervals of each sensor. The sensor sensitivity was
calculated by dividing the change in current (I) by the change in glycemia (C)
between the initial (before dextrose injection) and the peak status (after dextrose
injection) as follows: Sensitivity (nA/mM) = (Imax – I0) / (Cmax – C0)
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4.3. Results and Discussion
4.3.1. Preparation of Dex-loaded PLGA Microspheres
In order to control the release kinetics of Dex, microspheres were
fabricated using an oil-water emulsion process. We used PLGA (lactic and
glycolic copolymer ratio 50:50) as the biodegradable polymer. The microspheres
had a regular spherical morphology as shown in Fig. 4.1. The diameter of Dexloaded microspheres varied from 1.5 to 50 μm and the average diameter size
was 16.0 ± 2.3 μm as estimated from SEM images in three different areas.
Figure 4.1(A) shows that many Dex crystals were present around the
microspheres because an excess amount of Dex (50 mg in 80 mg of PLGA) was
used in the microsphere preparation to increase the Dex loading efficiency. Dex
has poor solubility in water, but is freely soluble in alcohols. Washing the
microspheres with methanol removed the Dex crystals [Fig. 4.1(B)].
The effect of the organic solvents on Dex encapsulation was investigated
using two different organic solvent systems. Methylene chloride (MC) is widely
used as an organic solvent for PLGA. Acetone and methanol are good solvents
for Dex. A constant ratio of PLGA (80 mg) to Dex (50 mg) and 5 mL of MC were
used in this study. Table 4.1 shows Dex loading efficiency and encapsulation
efficiency with different solvent systems. The amount of Dex loading and
encapsulation efficiency dramatically increased to 14.9 ± 0.51 and 38.9 ± 1.32 %,
respectively, when using acetone:MC (1:5), compared to methanol:MC (1:5) (3.3
± 0.24 and 8.5 ± 0.64 %). Because acetone is also a good solvent for PLGA, the
Dex-acetone solution is more miscible with the MC-polymer solution and thus,
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A

B

Figure 4.1.

SEM Morphology of the Dex-loaded PLGA Microspheres. (A) with
Dex crystals; (B) without Dex crystals after washing with methanol.
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Table 4.1.

Solvent Effect on the Amount of Dex Loading Efficiency and
Encapsulation Efficiency.

Solvent (v:v)

% of Dex Loading (/MS)

Encapsulation Efficiency (%)

Me-OH : MC (1:5)

3.3 ± 0.24

8.5 ± 0.64

Acetone : MC (1:5)

14.9 ± 0.51

38.9 ± 1.32
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A

B

Figure 4.2.

SEM Morphology of the Dex-loaded PLGA Microspheres/Collagen
Scaffold Composite. (A) x500 magnification; (B) x1,000
magnifications.
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the amount of Dex encapsulated in PLGA was higher in the acetone/MC cosolvent system than with the methanol/MC system due to a better continuous
phase.

4.3.2. Preparation of Dex-loaded Microspheres/Scaffold Composite System
To further in an effort suppress inflammatory response to implantable
glucose sensors, Dex-loaded microspheres were incorporated into the porous
NDGA-crosslinked collagen scaffolds. Microspheres suspension in either
Pluronic

F127

hydrogel

or

water

was

used

for

the

fabrication

of

microspheres/scaffold composites. We chose to add the microspheres to NDGAcrosslinked scaffolds to avoid Dex loss that would have resulted from the
crosslinking method in ethanol. Figure 4.2(A) shows that the microspheres were
uniformly distributed throughout the scaffold due to its open pores (with
diameters ranging from 20 to 100 μm) and high interconnectivity between the
pores. In a higher magnification image [Fig. 4.2(B)], the Dex-loaded
microspheres (1.5 – 50 μm) can be seen attached to the collagen scaffold matrix.
The effect of different suspensions on drug loading was evaluated. Figure
4.3 shows that the amount of Dex loading efficiency was directly proportional to
the initial microsphere-loading amount (5 to 20 mg/mL). Interestingly, the
microspheres/scaffold composite fabricated using hydrogel suspension had a
much higher loading efficiency than the composite fabricated using water
suspension. The Pluronic solution (20% concentration) being highly viscous
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Figure 4.3.

The Amount of Dex Loading in the Composite as Fabricated Using
Either Water or Hydrogel Suspension with Different Initial
Microspheres Loading Amounts. Results are shown as mean ± SD
(n = 4).
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allowed the addition of many microspheres to the scaffolds during the loading
process. In addition, Figure 4.4 shows that the amount of Dex loading decreased
from 566.5 ± 1.1 to 510.4 ± 9.0 µg/mg of scaffold after rinsing with water for the
microspheres loaded with water suspension. However, there was no significant
Dex loss after water rinsing in the composite fabricated using hydrogel
suspension. The Pluronic/microspheres mixtures were sol state in the ice bath
(below 4°C), but they were gelled at room temperature after the completion of the
loading process. We assume that all microspheres still remained in position
inside the scaffold after the rinsing step due to this sol-gel transition behavior of
the Pluronic suspension.

4.3.3. In vitro Drug Release Studies
Four in vitro release studies were performed in phosphate buffered saline
(PBS) under sink conditions for both microspheres and microspheres/scaffold
composite systems. Based on the loading efficiency results above, we chose to
fabricate a composite system using the Pluronic hydrogel suspension. At 3 day
or 7 day intervals, samples of the incubation medium were collected and Dex
concentration in the supernatant was determined by HPLC. Figure 4.5(A) and
4.5(B) show the cumulative Dex release profiles from the PLGA standard
microspheres and the PLGA microspheres/collagen scaffold composites,
respectively. An initial burst release (20 – 25 %) was observed within 6 – 7 days
post incubation for both the microspheres and composite system. The initial burst
release was probably due to residual Dex crystals on the surface of the
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Figure 4.4.

Hydrogel Suspension

The Amount of Dex Loading in the Composite as Fabricated Using
Either Water or Hydrogel Suspension after Rinsing with Water.
Results are shown as mean ± SD (n = 4).
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Figure 4.5.

Cumulative Dex Released from Standard Microspheres and Dexloaded Microspheres/Scaffold Composite During the In vitro
Release Studies in PBS at 37°C. The total amount of Dex released
into the PBS as a percentage of the total amount of Dex
encapsulated into the microspheres (A) and encapsulated into the
scaffold composites (B) was plotted as a function of the elapsed
time from the beginning of the release studies. Results are shown
as means ± SD (n = 4).
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microspheres [50,53]. For the three day interval sample collection shows that the
release of Dex from microspheres alone reached 90% release within 24 days,
while the composite system released 50% of Dex during the same period. The
composite system dramatically slowed the drug release compared to the
standard microspheres. This result may suggest that either collagen scaffold or
the hydrogel phase in the scaffold delayed Dex diffusion to the releasing media.
The release profile of both microspheres and composite system when
collected at 7 day intervals showed the same pattern with an initial burst release
and continued zero order release pattern between day 7 and day 21, probably
because of inadequate sink condition (PBS was replaced every 7 days).
Nonetheless, the release study with 3 day sample collection showed sustained
release of Dex from the microsphere/hydrogel/scaffold system over 1 month.

4.3.4. Implantable Glucose Sensors Covered with Microspheres/Scaffold
Composite System
We prepared coil-type glucose sensors with porous collagen scaffolds as
previously described [111]. Then, Dex-loaded microspheres were incorporated
into the scaffolds surrounding the sensors by soaking in microspheres-Pluronic
suspensions. With a light microscope, we confirmed that the microspheres
thoroughly surrounded the sensor surface [Fig. 4.6(A)]. In a higher magnification
image [Fig. 4.6(B)], the Dex-loaded microspheres were observed to be uniformly
distributed inside the pore structure of the collagen scaffold.
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A

B

Figure 4.6.

Light Microscope Photographs of the Implantable Glucose Sensing
Element with Dex-loaded Microspheres/Scaffold Composite. (A)
Working electrode; (B) x100 magnification of the scaffold region.
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The effect of the microspheres on the function of sensors was investigated
by varying the glucose concentration from 5 to 15 mM. The sensitivity change for
each sensor before and after microspheres application with different suspensions
is shown in Figure 4.7. We observed a slight decrease of the sensitivity of
sensors with microspheres fabricated using either water or hydrogel suspension,
compared to the sensors without microspheres. However, there was no statistical
difference before and after microspheres application (p > 0.05; Student’s t-test).
Therefore, adding microspheres around the sensors with scaffold did not
negatively intact the function of the sensors.

4.3.5. In vivo Performance of Sensors with Dex-loaded Microspheres/
Scaffold Composite System
Implantable glucose sensors with Dex-loaded microspheres/scaffold
composite were implanted subcutaneously in the back of rats and their sensitivity
measured for up to 28 days or until there was no amperometric response.
Because of higher Dex loading, we chose to fabricate the composite system
using the Pluronic hydrogel suspension containing 40 mg/mL of Dex-loaded
microspheres. Figure 4.8 shows the percent sensitivity change of the sensors
during the 2 week study. The sensitivity of the sensors with composite was
compared to our previous in vivo data results (without microspheres; control,
NDGA-crosslinked scaffold, GA-crosslinked scaffold). The sensors with the
composite system retained above 50% of their original sensitivity at 2 weeks,
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Figure 4.7.

Effect of Adding PLGA Microspheres in the Scaffold on Glucose
Sensor Sensitivity with Different Suspensions. (A) Water
suspension; (B) Pluronic F127 hydrogel suspension. Results are
shown as means ± SD. (n = 4). *Indicates no statistically significant
differences before / after incorporation of microspheres (p > 0.05).
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NDGA-crosslinked Collagen Scaffold after 2 Weeks Post
Implantation.
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while the sensitivity of the control sensors, sensors with NDGA-crosslinked
scaffolds and sensors with GA-crosslinked scaffolds decreased to 42%, 30%,
and 15%, respectively. We believe that this was because the locally delivered
Dex effectively decreased the inflammatory response to the sensors. However, it
was observed that only 2 out of 8 sensors with the composite scaffolds
functioned at 2 weeks. We suggest that the reason for the functional failure may
be related to the reference electrode [Fig. 4.9(A)]. Figure 4.9(B) shows a dense
fibrous capsule surrounding the reference electrode. In this study, we applied
Dex-loaded microspheres/scaffold composite around the working electrode but
not around the reference electrode. For this study, we did not coil the reference
electrode to avoid micro-shorting caused by touching reference electrode coil
(Ag/AgCl wire) to the uncovered Pt/Ir wire. However, this different reference
electrode geometry may have induced a larger inflamed area of tissue.
After 4 weeks, we excised non-functional sensors and tested them ex vivo
(with tissue) in 5 mM and 15 mM glucose/PBS. Subsequently, the sensors were
removed from the surrounding tissue and tested in vitro. Figure 4.10 shows the
amperometric response curves of an explanted glucose sensor with and without
fibrous capsule tissue. It was found that the sensor with its fibrous capsule
responded poorly (line A, sensitivity = 1.5 nA/mM) to changes in glucose
concentration, while the sensor regained its initial function (line B, sensitivity =
15.4 nA/mM) after removing the surrounding tissue. These shows that the dense
fibrous capsule tissue which forms around the reference electrode can also affect
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Figure 4.9.

Light Microscope Photographs of Implantable Glucose Sensors. (A)
Reference and working electrode region; (B) Dense fibrous capsule
tissue surrounding the reference electrode (R - reference electrode,
W - working electrode).
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Figure 4.10. Amperometric Response Curves of the Explanted Non-functioned
Glucose Sensors after 4 Weeks Post Implantation. (A) Ex vivo
response of the sensor with surrounding fibrous capsule tissue; (B)
In vitro response of the sensor after removing surrounding the
fibrous capsule tissue, after glucose concentration increase from 5
to 15 mM.
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the sensor. Thus, the reference electrode could also be surrounded by the
composite system described in this paper.

4.3.6. Suppression of Inflammation to Dex-loaded Microspheres/Scaffold
Composite System
To confirm the anti-inflammatory response of the Dex-loaded
microspheres/scaffold composite (40 mg/mL of microspheres, Pluronic F127
hydrogel suspension), we implanted the composites (without sensors)
subcutaneously in rats. Standard NDGA-crosslinked scaffolds (without
microspheres) were implanted for comparison. The histological results (H&E
stain) for sampled at 2 and 4 weeks after implantation for both the scaffold alone
and the composite scaffold are shown in Figure 4.11. The inflammatory cells
were stained as purple, while normal cells were stained as pink. A very strong
inflammatory response was shown around the control scaffold 2 weeks after
implantation [Fig. 4.11(A)]. Predominant polymorphonuclear leukocytes (PMNs)
with monocytes and macrophages were observed and a dense connective tissue
layer (fibrous capsule) surrounded the periphery of the scaffold. In contrast, the
inflammatory response to the Dex-loaded composites [Fig. 4.11(B)] was
diminished compared to the control scaffold. The histological results after one
week implantation are not shown as there was no noticeable difference between
the control scaffold and the Dex-loaded composites. After 4 weeks post
implantation, the inflammatory response to the Dex-released composites was low
[Fig. 4.11(D)] while a severe inflammatory response with a thick fibrous capsule
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Figure 4.11. Hematoxylin and Eosin Stained Sections of Tissue Surrounding
Porous Scaffolds in Rats. (A) NDGA-crosslinked scaffold; (B) Dexloaded microspheres / NDGA-crosslinked scaffold composite after
2 weeks post implantation; (C) NDGA-crosslinked scaffold; (D)
Dex-loaded microspheres / NDGA-crosslinked scaffold composite
after 4 weeks post implantation (CT - connective tissue, SCscaffold).

104

was present around the scaffold without Dex-loaded microspheres [Fig. 4.11(C)].
These results demonstrate that the Dex released from the microspheres/scaffold
greately reduced the inflammatory response to the scaffold.
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4.4. Conclusions
In this study, we prepared Dex-loaded PLGA microspheres and
incorporated then into three dimensional porous type I collagen scaffolds
(crosslinked with NDGA) around implantable glucose sensors. The fabricated
composite has effectively loaded Dex and sustained release of Dex for at least
one month. The composite system did not significantly alter the function of the
sensors in vitro despite the high amount of microspheres. After 2 weeks in vivo,
the sensitivity of sensors with the composite system remained higher than for
other sensors without the composite system. The histological results showed that
the inflammatory response was lowered using the Dex-loaded composite scaffold
when compared to the inflammatory response to the scaffolds without Dexloaded microspheres at 2 and 4 weeks after implantation. These results showed
that our Dex-loaded composite system reduces inflammation around the
implanted glucose sensors tips and could potentially improve their function and
lifetime.
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CHAPTER 5
SUGGESTIONS FOR FUTURE STUDY

The best tissue environment for implantable biosensor is vascularized
tissue around sensor. The control of neovascularization has recently focused on
the use of angiogenic growth factors such as VEGF and PDGF. Norton et al.
[52,110] reported that they fabricated hydrogel sensor coatings containing Dex
and/or VEGF to minimize foreign body response and to promote angiogenesis.
Klueh et al. [62,63] induced significant neovascularization surrounding an
implanted sensor using a VEGF-cell-fibrin gene transfer system.
The goal future studies will be to introduce local delivery with microsphere
systems to release angiogenic factors (VEGF, PDGF) and anti-inflammatory
drugs (i.e. dexmethasone), concurrently. Since Dex can lead to an antiangiogenesis effect along with an anti-inflammatory response, the optimization of
the concentrations of either angiogenic factors or Dex will play an important role
in the dual release system. The future investigations should determine how to
control neovasculrature density without foreign body response around implanted
glucose sensors. In addition, we found a dense fibrous capsule surrounding the
reference electrode in Chapter 4. In future investigations, the reference electrode
should also be coated with the same approach utilized for the working electrode.
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Appendix A: Protocol – Preparation Procedure of Coil-type Glucose
Sensors

A.1. Coiling of Platinum-iridium (Pt-Ir) Wires
- Cut 0.125 mm Pt-Ir wires into 4-7 cm long.
- Remove the top Teflon tube (1 cm).
- Polish the bare wire with a swab in toothpaste.
- Ultrasonic cleaning the platinum surface in pure water for 5 min.
- Coil the stripped wire around a 30 G1/2 needle.
- Ultrasonic cleaning the platinum surface in pure water for 5 min. again.
- Carefully pass through a cotton thread the coils then cut the two ends of the
thread, do not let any cotton silks leave out the coils.

A.2. Enzyme Coating
- Glucose oxidase solution preparation:
300 μL pure water
12 mg Bovine serum albumin (BSA)
2.5 mg glucose oxidase (GOD)
4 μL glutaraldehyde (50% v/v)
- Dip-coatings (3 times).
- Let it dry 1 hour at room temperature.
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Appendix A (Continued)

A.3. Epoxy-PU Coating
- Coating solution preparation:
Tetrahydrofunan (THF) 4 mL
PU 45 mg
Brij30 5mg
Epoxy adhesives 50mg
- Dip-coatings (3 times) & Dry at room temperature for 30-60 min.
- Coat two-end of coil & Dry at room temperature for 30-60 min.
- Cure at 80-120°C for 60 min.
- Place in PBS prior to use (at least 1 day for membrane swelling).
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Appendix B: Protocol – Measurement of Sensor Function

B.1. Preparation of Measurement
- Testing solution:
PBS
5 mM glucose/PBS solution
100 mM glucose/PBS solution
- Potentiostat options:
Select chronoamperometry
Set applied potential at 0.7V
- Cell setup:
8 ml of 5 mM glucose/PBS in a 10 mL glass beaker
Connect counter and reference clamps to the Ag/AgCl electrode
Connect working electrode to the glucose sensor

B.2. Response Time and Slope Measurement
- Run the program until the current (I5mM) reach a stable level.
- Add 941 μL of 100 mM Glucose/PBS into the cell and continue to record the
current change until the second current (I15mM) level stable.
- Response time may be expressed as T95%(sec.) [Fig. B.1].
- Sensitivity (S) can be roughly calculated by:
S (nA/mM) = (I15mM - I 5mM) / (C15mM - C5mM) = Δ I / 10
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Current (nA)

I15mM

Max. ΔI

95% ΔI
I5mM

T95%

Time (sec.)

Figure B.1. Amperometric Response Curve.

B.3. Preparation of Calibration Plot
- Run the program until the background current reach a stable level.
- Step-add x μL of 100mL Glucose/PBS into the cell every 500 sec.
- Obtained a group of corresponding currents (I1 - I7).
- Draw the current-concentration dependence.
- Response sensitivity can be obtained by calculating the slope of the current ( I )
vs glucose concentration (C) linearity relationship.
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Table B.1. Changes of Glucose Concentration in the Cell.
X (mL) of 100 mM
glucose/PBS solution

Glucose concentration (mM)

Current (nA)

0.163

2

I1

0.258

5

I2

0.467

10

I3

0.523

15

I4

0.589

20

I5

0.667

25

I6

0.762

30

I7
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Appendix C: Protocol – Implantation of Glucose Sensors in the Rat and
Measurement of Sensor Function In vivo

C.1. Surgery Materials
- Male Sprague Dawley Out bred Rats (375g – 399 grams).
- Isofluorane anesthesia machine.
- Surgical clippers and water circulating heating board.
- Sterile bench pads, drapes, surgery packs with scalpels, and probes.
- 3-0 Proline sutures.
- Sterile and non-sterile gloves.
- Lab note book, pen and sharpie.
- Sterile and un-sterile gauze.
- Puralube ointment for eyes.
- 50cc of D50 glucose solution.
- Sterile towels (to keep animal warm).
- Chlorhexidine / Betadine solutions.
- Isopropyl alcohol.
- 50cc of D50 glucose solution.

C.2. Glucose Monitoring and Testing Apparatus
- Apollo 4000 Free Radical Analyzer.
- FreeStyle Blood Glucose Monitoring System.
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C.3. Sterilization and Pre-calibration of Glucose Sensors
- All sensors will be sterilized by 70% ethanol.
- Each sensor will be incubated in a sterile 5mM glucose solution three days
before implantation.
- On the day before implantation, each sensor will be pre-calibrated with 5 mM
and 15mM glucose solutions which are sterilized by a sterile syringe filter.
- After obtaining the sensitivity value of each individual sensor, the sensor will be
stored in sterile distilled water.

C.4. Protocol for Animal Surgery
- All surgical instruments and other items to be sterilized will be autoclaved at
260°C for 25 min. doubled wrapped or in the sterilization pouch.
- Surgery will be conducted on a clean surface wiped with disinfectant before and
after use.
- A Continuous Flow Gas Anesthesia System (flow meter, vaporizer, tubing and
connectors) will be used to deliver Isoflourane to the rats. The animals will first
be placed in an induction chamber for induction of anesthesia and then the gas
will be delivered through a rat mask when surgery is performed. Position the
first rat on the water circulating heating board for rodents using tape to insure
positioning of the body, head and rat mask.
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- Each of the rats that are under anesthesia will have their eyes lubricated with
Puralube ointment.

C.5. Implantation of Sensors (Long Wire Sensors)
- An area on the dorsal aspect of each rat will be shaved at the cervical region to
the lumbar region.
- The skin will be surgically prepped using 3 scrubs of 2% Chlorhexidine and
painted with Betadine and left to dry.
- A sterile fenestrated drape will be placed on the rat.
- Each rat will have 2 sensors implanted.
- Using the scissors a 1.5 cm incision is made at the dorsal midline 3cm below
the inter-scapular area. Lateral incisions are made 1cm below the interscapular area 1cm lateral to the dorsal midline on either side.
- The 14-gauge. I.V. catheter was inserted subcutaneously toward the incision
from the 4 - 5 cm lower back region.
- Withdraw the 14-gauge needle leaving the catheter in place.
- The sensor can then be carefully advanced, using thumb and forceps, through
the catheter without touching the distal end of the sensor.
- The sensor was secured to the skin by passing a 3-0 Prolene suture through
the small gap of the wound clip on the sensor wires.
- The incision was sutured using 3-0 Prolene.
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- The cannula was then retracted, leaving the sensor in the subcutaneous tissue.
- The sensor was secured to the skin by passing a 3-0 Prolene suture through
the small gap of the wound clip on the sensor wires.
- The incision was sutured using 3-0 Prolene.
- The cannula was then retracted, leaving the sensor in the subcutaneous tissue
(For short wire sensors - the sensors were directly implanted through the
incision without using a cannula).

C.6. Sensors Testing
- Sensor testing will be performed with two anesthetized rats at a time. A total of
8 sensors will be tested per day.
- The implanted sensors wires will be attached to the Apollo 4000 potentiostat
and a 0.7V vs. Ag/AgCl potential will be applied to four sensors. At the same
time, four response current curves will be continuously recorded on digital
display.
- After the one hour “run-in period” is complete a relatively stable signal (I1) from
the sensors will be recorded.
- Using the Freestyle™ glucometer, the low blood glucose level (C1) will
established using 1/3 micro liter of blood from the rat tail.
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- After a stable signal is obtained from the sensors, 2.0 g/kg rat body weight of
50% glucose/water solution will be administered intraperitoneally using a 27
gauge IV needle.
- An increase in the blood glucose of the rat will correspond with a rise in the
slope of the current-time curve of each sensor. Previous in vivo studies have
demonstrated that plasma glucose will increase to a plateau (I2). This time
interval is long enough to establish equilibrium between plasma and
subcutaneous glucose concentrations.
- More blood tests will be made every 5-10 minutes after injection of glucose until
the high glucose level (C2) is stable.
- A blood-calibrated sensitivity (S) can be calculated:
S (nA / mM) = I2 - I1 / C2 - C1
- The same test will be performed on days 7, 14, 21, and 28 to establish the
sensitivity of the sensors over time.

C.7. Animal Recovery
- Remove the animal from the anesthesia device.
- Gently place the animal back into its cage.
- Place half the cage onto a circulating heating broad or place an electric heating
pad in the cage to cover half the area of the cage floor.
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- Once fully recovered from anesthesia, replace the water, food, but no toys or
tunnels in the cage with the animal.
- Daily observation of the rats with notes in the lab book should be done.
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